Agilent Technologies (A)

Company ID: 74 | CIK: 0001090872
10-Q view:
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data

Business Unit / Product Segments

No 10-Q data

Major Customers (% of Revenue)

Operational KPIs

Backlog (backlog)

Total orders (bookings)

No 10-Q data

Capital expenditures (capacity)

No 10-K data

Customers (customers)

No 10-Q data

Female Employees (headcount)

Orders received (orders_received)

Bank guarantees and letters of credit (other)

No 10-K data

Book-to-bill ratio (other)

No 10-K data

Capital expenditures (other)

No 10-K data

Cash held outside U.S. (other)

No 10-K data

Common Stockholders (other)

No 10-Q data

Common shares outstanding (other)

No 10-Q data

Common stock outstanding (other)

No 10-Q data

Common stockholders (other)

No 10-Q data

Common stockholders of record (other)

No 10-Q data

Consumer electronics revenue share (other)

No 10-Q data

Contract assets (other)

No 10-K data

Contract liabilities (other)

No 10-K data

Countries served (other)

No 10-Q data

Countries with service delivery (other)

No 10-Q data

Countries with service operations (other)

No 10-Q data

Cumulative workforce reduction (other)

No 10-Q data

Days Sales Outstanding (other)

Days sales outstanding (other)

Days' sales outstanding (other)

No 10-K data

Direct sales and service personnel (other)

No 10-Q data

Direct service countries (other)

No 10-Q data

Distributor revenue share (other)

No 10-Q data

EM revenue mix (other)

No 10-K data

Effective tax rate (other)

No 10-K data

Electronic measurement revenue mix (other)

No 10-Q data

Employees pending termination (other)

No 10-K data

Employees terminated (other)

No 10-K data

Extended warranty balance (other)

No 10-K data

FX forward contracts open (other)

No 10-K data

FX impact on revenue (other)

No 10-K data

FY05 Plan job reductions (other)

No 10-Q data

Facilities exited (other)

No 10-Q data

Facility space vacated (other)

No 10-K data

Female employee share (other)

No 10-Q data

Female employees share (other)

No 10-Q data

Foreign currency impact on revenue (other)

No 10-K data

Foreign exchange forward contracts (other)

No 10-K data

Gross margin (other)

No 10-K data

HP ownership stake (other)

No 10-K data

Installed base of 93000 SOC test systems (other)

No 10-K data

Inventory Days on Hand (other)

Inventory days on hand (other)

Inventory days on-hand (other)

Inventory days' on-hand (other)

No 10-K data

Market value held by non-affiliates (other)

No 10-Q data

Number of Reportable Segments (other)

Open FX forward contracts (other)

No 10-K data

Open foreign exchange forward contracts (other)

No 10-K data

Open forward contracts (other)

No 10-K data

Operating margin (other)

No 10-K data

Order growth (other)

No 10-K data

Outsourced manufacturing share (other)

No 10-Q data

Outstanding Common Shares (other)

No 10-Q data

Outstanding Shares (other)

No 10-Q data

Outstanding common shares (other)

No 10-Q data

Outstanding shares (other)

No 10-Q data

Patents issued annually (other)

No 10-Q data

Planned headcount reduction (other)

No 10-K data

Products in production (other)

No 10-Q data

Purchase commitments (other)

No 10-K data

Quarterly operating cost structure (other)

No 10-Q data

R&D Expenditures (other)

No 10-Q data

R&D expenditures (other)

No 10-Q data

Remaining share repurchase authorization (other)

No 10-K data

Research and development expenditures (other)

No 10-Q data

Research and development expense (other)

No 10-Q data

Restructuring and asset impairment charges (other)

No 10-K data

Restructuring liability (other)

No 10-K data

Restructuring savings run-rate (other)

No 10-Q data

Return on invested capital (other)

No 10-Q data

Revenue from China (other)

No 10-Q data

Revenue from Japan (other)

No 10-Q data

Revenue generated outside the U.S. (other)

No 10-Q data

Revenue growth (other)

No 10-K data

Revenue mix (other)

No 10-Q data

Revenue outside U.S. (other)

No 10-Q data

Sales, service and support engineers (other)

No 10-Q data

Semiconductor design centers (other)

No 10-Q data

Semiconductor test product mix (other)

No 10-Q data

Service delivery countries (other)

No 10-Q data

Shares of common stock outstanding (other)

No 10-Q data

Shares outstanding (other)

Shares repurchased (other)

No 10-K data

Standard warranty accrual (other)

No 10-K data

Stock options outstanding (other)

Stockholders of Record (other)

No 10-Q data

Stockholders of record (other)

No 10-Q data

Suppliers (other)

No 10-Q data

Temporary wage reduction (other)

No 10-K data

Test design wins (other)

No 10-K data

Total gross margin (other)

No 10-K data

US dollar revenue share (other)

No 10-Q data

USD-denominated revenue share (other)

No 10-K data

Warranty accrual balance (other)

No 10-K data

Workforce reduction (other)

Workforce reductions (other)

No 10-K data

Production volume (production_volume)

No 10-Q data

Manufacturing sites (properties)

Revenue, Remaining Performance Obligation, Amount (rpo)

Manufacturing Space (square_footage)

Patient monitors supplied (units_shipped)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

Demographics

No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data
No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No point-in-time HCM metrics found.

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-07-31restructuringin_progress2027-01-31GlobalAll three segments (unallocated)USD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced in Q3 FY2026 (exact date not disclosed); workforce reduction to optimize management structure. $15M expense recorded in both the three and nine months ended July 31, 2026; $9M liability remaining at quarter-end. Expected annual cost savings of $30M-$35M. Number of employees affected not disclosed.
2026-07-31restructuringin_progress2026-10-31GlobalAll three segments (unallocated)USD 28 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced in Q2 FY2025 (exact date not disclosed); $28M expense recorded in the nine months ended July 31, 2026 (approximately zero in the three months ended). $4M liability remaining at quarter-end; $109M total expense since inception. Expected annual cost savings of $90M-$95M. Number of employees affected not disclosed.
2026-07-31acquisition_additioncompleted2026-06-242026-06-24GlobalLife Sciences and Diagnostics Marketsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquired 100% of BC Midco I, Inc. for $950M net consideration; results consolidated from acquisition date. Headcount added not disclosed; MD&A attributes the increase in total headcount primarily to this acquisition.
2026-07-31restructuringin_progress2026-07-012027-01-31GlobalAll segmentsUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY26 Plan implemented in Q3 FY26 to optimize management structure. Expected to reduce annual costs by $30-35 million. Completion expected by Q1 FY27.
2026-07-31restructuringin_progress2025-04-012026-10-31GlobalAll segmentsUSD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY25 Plan announced in Q2 FY25. $28 million expense recorded in nine months ended July 31, 2026. Expected completion by end of FY26.
2026-07-31acquisition_additioncompleted2026-06-242026-06-24GlobalLife Sciences and Diagnostics Marketsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0
Acquired 100% of Biocare for $950 million. Headcount increase attributed to this acquisition in MD&A.
2026-07-31restructuringin_progressEmployee Severance [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-07-31restructuringin_progressUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-07-31restructuringin_progressEmployee Severance [Member] / FY26 Restructuring Plan [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-07-31restructuringin_progressEmployee Severance [Member] / FY25 Restructuring Plan [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-07-31restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-04-30restructuringin_progress2025-01-312026-10-31GlobalAll three business segments (Life Sciences and Diagnostics Markets, Agilent CrossLab, Applied Markets)USD 28 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced during fiscal Q2 2025 (quarter ended 2025-01-31); exact announcement date not disclosed. Workforce reduction via severance; no employee count disclosed. Charge is six months ended 2026-04-30 ($8M in Q2 alone); $5M liability remains at quarter end; total expense since inception $109M. Expected to substantially complete by end of fiscal 2026.
2026-04-30acquisition_additionannounced2026-03-062026-10-31Not disclosedLife Sciences and Diagnostics MarketsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Definitive agreement to acquire 100% of BC Midco I, Inc. (Biocare) for ~$950M cash; no headcount added disclosed. Closing may occur in fiscal Q3 2026 or no later than fiscal year-end 2026.
2026-04-30restructuringin_progress2025-04-302026-10-31GlobalAll segmentsUSD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY25 Plan announced in Q2 FY25. $28M expense recorded in six months ended April 30, 2026. Expected to substantially complete by end of fiscal year 2026. Employee count not disclosed for current period activity.
2026-04-30restructuringin_progressEmployee Severance [Member] / FY25 Restructuring Plan [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-04-30restructuringin_progressCost of Sales [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-04-30restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-04-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-04-30restructuringin_progressUSD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-04-30restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-31restructuringin_progress2026-10-31GlobalAll three reportable segmentsUSD 20 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Workforce reduction plan announced in fiscal year 2025 second quarter to optimize management structure; no employee count disclosed. Q1 FY2026 charge of $20M ($5M cost of products and services, $15M SG&A); liability of $16M at quarter-end; total expense since inception $101M; expected annual cost savings of $90M-$95M. Announcement date not specified beyond 'second quarter of fiscal year 2025'.
2026-01-31restructuringin_progress2025-04-012026-10-31GlobalAll segmentsUSD 20 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY25 Plan announced in Q2 FY25. $20M expense recorded in Q2 FY26. Expected to substantially complete by end of fiscal year 2026. Employee count not disclosed for this period.
2026-01-31restructuringin_progressEmployee Severance [Member] / FY25 Restructuring Plan [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-31restructuringin_progressCost of Sales [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-31restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-31restructuringin_progressUSD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-31restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-10-31restructuringin_progress2026-04-30GlobalAll three operating segments; management structure optimizationUSD 81 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
FY25 Plan announced in Q2 fiscal 2025 (February–April 2025; exact date not disclosed) to optimize the management structure. Headcount affected not disclosed. FY2025 expense of $81M comprises severance, other personnel costs and $18M non-cash accelerated share-based compensation; $46M cash paid, $18M liability remaining at 2025-10-31. Expected annualized savings of $75–80M. Completion date derived from filer's statement of substantial completion by Q2 fiscal 2026 (quarter ending April 30, 2026).
2025-10-31restructuringcompleted5003%GlobalAll three operating segments; company-wide workforce reductionUSD 1 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
FY24 Plan initiated in Q3 fiscal 2024 (May–July 2024; exact date not disclosed), comprising a reduction of approximately 500 regular employees (~3% of global workforce). All workforce management actions and payments were completed during fiscal 2025; FY2025 expense was $1M (cumulative program cost since inception $73M). Headcount reduction originally executed in fiscal 2024 per prior filings; captured here at plan completion as disclosed in the current 10-K.
2025-10-31restructuringin_progress2025-05-312026-04-30GlobalAll three operating segments; management structure optimizationUSD 81 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Announced in the second quarter of fiscal year 2025; date shown is quarter-end approximation as no exact date given. Expected to substantially complete by Q2 FY2026 (approximate completion date shown is quarter-end). Employees affected not disclosed. Expected annual cost savings of approximately $75-80 million. $18 million liability remained at 2025-10-31. Prior FY24 and FY23 plans (500 and 400 employees respectively) had all workforce actions completed before FY2025; only residual expenses of $1 million (FY24 Plan) were recorded in FY2025 and are not extracted as separate actions.
2025-10-31restructuringin_progress2025-01-012026-06-30GlobalAll SegmentsUSD 81 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY25 Plan announced in Q2 FY25 to optimize management structure. Expected to substantially complete by Q2 FY26. Total expense of $81 million recorded in FY25.
2025-10-31restructuringcompleted5003%2024-07-01GlobalAll SegmentsUSD 73 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY24 Plan initiated in Q3 FY24. Reduction of approximately 500 regular employees (3% of global workforce). All workforce management actions and payments completed.
2025-10-31restructuringcompleted4002%2023-07-01GlobalAll SegmentsUSD 50 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY23 Plan initiated in Q4 FY23. Reduction of approximately 400 regular employees (2% of global workforce). All workforce management actions and payments completed.
2025-10-31restructuringin_progress2025-04-012026-04-01GlobalAll segmentsUSD 81 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
FY25 Plan announced in Q2 FY25 to optimize management structure. Expected to substantially complete by Q2 FY26. Charge includes severance and personnel costs. Employee count not explicitly disclosed for this specific plan in the text, though total headcount reduced by ~200 net from prior plans.
2025-10-31restructuringcompleted2024-07-01GlobalAll segmentsUSD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
FY24 Plan initiated in Q3 FY24. Reduced headcount by approx 500 employees (3% of global workforce). Plan completed in FY25 with $1M additional expense recorded.
2025-10-31restructuringcompleted2023-10-01GlobalAll segmentsUSD 4 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
FY23 Plan initiated in Q4 FY23. Reduced headcount by approx 400 employees (2% of global workforce). Plan completed in FY25 with $4M expense recorded in FY24.
2025-10-31restructuringin_progressEmployee Severance [Member]USD 82,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-10-31restructuringin_progressFacility Closing [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-10-31restructuringin_progressUSD 82,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-10-31restructuringin_progressCost of Sales [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-10-31restructuringin_progressResearch and Development Expense [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-10-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-10-31restructuringin_progressEmployee Severance [Member] / FY25 Restructuring Plan [Member]USD 81,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-10-31restructuringin_progressEmployee Severance [Member] / FY24 Restructuring Plan [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-10-31restructuringin_progressSegment Reporting, Reconciling Item, Corporate Nonsegment [Member]USD 82,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-10-31restructuringin_progress500FY24 Restructuring Plan [Member]restructuring_footnote
f5-10k / no-ai-xblr
2025-07-31restructuringin_progress2025-02-012026-04-30All three business segmentsUSD 73 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML
FY25 Plan announced in Q2 fiscal 2025 to optimize management structure; workforce reduction expense includes severance and personnel-related costs; $17 million recorded in Q3 and $73 million since inception; expected to substantially complete by Q2 fiscal 2026; estimated $75-80 million annual cost reduction; liability of $23 million at July 31, 2025
2025-07-31restructuringcompleted2024-08-012025-07-31All three business segmentsUSD 73 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML
FY24 Plan announced in Q3 fiscal 2024 to reduce costs in response to macroeconomic conditions; all workforce management actions and payments completed as of July 31, 2025; $1 million change-in-estimate expense recorded in the nine months ended July 31, 2025; expected ~$100 million annual cost reduction
2025-07-31restructuringin_progress2026-04-30All three business segmentsUSD 73 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced in second quarter of fiscal 2025 (exact date not disclosed); workforce reduction to optimize management structure. Expense of $73M recorded in nine months ended July 31, 2025 ($17M in Q3); expected annual cost savings of $75M-$80M. Number of employees affected not disclosed.
2025-07-31restructuringcompletedAll three business segmentsUSD 73 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced in third quarter of fiscal 2024 (exact date not disclosed); all workforce management actions and payments completed as of July 31, 2025. Total expense since inception $73M, of which $1M recorded in nine months ended July 31, 2025 due to changes in estimates. Expected annual cost savings of approximately $100M. Number of employees affected not disclosed.
2025-07-31restructuringin_progress2025-04-012026-04-30GlobalAll segmentsUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY25 Plan announced in Q2 FY25 to optimize management structure. $17M expense recorded in Q3 FY25. Expected completion by Q2 FY26.
2025-07-31restructuringcompleted2024-07-01GlobalAll segmentsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY24 Plan announced in Q3 FY24. Completed all workforce actions as of July 31, 2025. $1M expense recorded in YTD FY25 due to changes in estimates.
2025-07-31restructuringin_progressEmployee Severance [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-31restructuringin_progressCost of Sales [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-31restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-31restructuringin_progressUSD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-31restructuringin_progressEmployee Severance [Member] / FY25 Restructuring Plan [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-31restructuringin_progressEmployee Severance [Member] / FY24 Restructuring Plan [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-31restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-04-30restructuringin_progress2025-02-012026-04-30All three business segmentsUSD 56 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML
FY25 Plan announced in Q2 fiscal 2025 to optimize management structure; workforce reduction charge includes severance and personnel-related costs; expected to substantially complete by Q2 fiscal 2026; estimated $75-$80 million in annual cost savings when completed; liability of $51 million at April 30, 2025
2025-04-30restructuringin_progress2024-08-012025-10-31All three business segmentsUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML
FY24 Plan announced in Q3 fiscal 2024 to reduce costs in response to macroeconomic conditions; workforce actions substantially complete as of April 30, 2025 with remaining payments expected by end of fiscal 2025; $1 million change-in-estimate charge in the six months ended April 30, 2025; expected ~$100 million annual cost savings
2025-04-30restructuringcompleted2023-11-01All three business segmentsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML
FY23 Plan substantially complete; cash payments of $1 million and $2 million settled in the three and six months ended April 30, 2025, respectively
2025-04-30restructuringin_progress2026-07-31All three reportable segments (Life Sciences and Diagnostics Markets, Agilent CrossLab, Applied Markets)USD 56 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced in the second quarter of fiscal 2025 (exact date not disclosed); workforce reduction to optimize management structure. Charge of $56M recorded in both the three and six months ended April 30, 2025. Expected to substantially complete by Q2 FY2026; estimated annual cost savings of $75-80 million. Number of employees affected not disclosed. Liability balance of $52M at April 30, 2025 (includes $1M FY24 Plan balance).
2025-04-30restructuringcompleted2025-10-31All three reportable segmentsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced in the third quarter of fiscal 2024 (exact date not disclosed). Workforce management actions substantially complete as of April 30, 2025; remaining payments expected to settle by end of fiscal 2025. $1M charge recorded in the six months ended April 30, 2025 due to changes in estimates; total expense since inception $73M. Employees affected not disclosed.
2025-04-30restructuringcompletedAll three reportable segmentsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
All workforce management actions and payments substantially completed; $2M of cash payments settled in the six months ended April 30, 2025. Total expense since inception $50M. Employees affected not disclosed.
2025-04-30restructuringin_progress2025-02-012026-04-30GlobalAll segmentsUSD 56 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY25 Plan announced in Q2 FY25 to optimize management structure. Expected to substantially complete by Q2 FY26. Includes severance and personnel-related costs.
2025-04-30restructuringcompleted2024-08-012025-10-31GlobalAll segmentsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY24 Plan announced in Q3 FY24. Substantially completed workforce actions; remaining payments expected by end of FY25. Charge reflects changes in estimates.
2025-04-30restructuringcompleted2023-11-01GlobalAll segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY23 Plan. Substantially completed all workforce management actions and payments. Settled cash payments of $1M in Q2 FY25.
2025-04-30restructuringin_progressEmployee Severance [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-04-30restructuringin_progressCost of Sales [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-04-30restructuringin_progressResearch and Development Expense [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-04-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-04-30restructuringin_progressUSD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-04-30restructuringin_progressEmployee Severance [Member] / FY25 Restructuring Plan [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-04-30restructuringin_progressEmployee Severance [Member] / FY24 Restructuring Plan [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-04-30restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-31restructuringin_progress2024-08-012025-04-30All three business segmentsUSD 73 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML
Workforce reduction announced Q3 FY2024; majority completed by end of FY2024, remaining activities expected substantially complete by Q2 FY2025. Approximately $1 million in changes of estimate recorded in Q1 FY2025. Expected to reduce annual cost of sales and operating expenses by approximately $100 million. Liability of $4 million at January 31, 2025.
2025-01-31restructuringcompleted2023-01-01All three business segmentsUSD 50 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML
Workforce management actions substantially completed; $1 million cash settled in Q1 FY2025, remaining $1 million accrual to be settled in Q2 FY2025.
2025-01-31restructuringin_progress20242025-04-30GlobalAll three business segments (workforce reduction)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced in Q3 FY2024; $1M charge in Q1 FY2025 reflects changes in estimate; $5M accrual balance at quarter end; expected annual cost savings of approximately $100M; number of employees affected not disclosed
2025-01-31restructuringcompleted20232025-04-30GlobalAll three business segments (workforce reduction)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Workforce actions substantially completed; $1M accrual remaining to be settled in Q2 FY2025; no restructuring expense recorded in Q1 FY2025; number of employees affected not disclosed
2025-01-31restructuringin_progress2024-07-012025-04-30GlobalAll segmentsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Fiscal Year 2024 Plan. Majority of workforce reduction completed by end of FY2024. Remaining activities expected to substantially complete by Q2 FY2025. $1M expense recorded in Q1 FY2025 due to changes in estimate.
2025-01-31restructuringcompleted2023-07-012025-04-30GlobalAll segmentsUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Fiscal Year 2023 Plan. Substantially completed all workforce management actions. $1M cash payments settled in Q1 FY2025. Remaining accrual of $1M to be settled in Q2 FY2025.
2025-01-31restructuringin_progressEmployee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-31restructuringin_progressCost of Sales [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-31restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-31restructuringin_progressUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-31restructuringin_progressFY24 Restructuring Plan [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-31restructuringin_progressEmployee Severance [Member] / FY24 Restructuring Plan [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-31restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-10-31restructuringin_progress5003%2024-072025-04-30All three business segments (charges not allocated to segment results)USD 72 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
FY24 Plan initiated in fiscal Q3 2024 (May–July 2024); announcement_date reflects the quarter-end month since the exact date is not disclosed. Involves reduction of approximately 500 regular employees, about 3 percent of the global workforce; majority of the reduction completed in FY2024 with remaining activities expected substantially complete by end of fiscal Q2 2025 (April 30, 2025). FY2024 charge covers severance, accelerated share-based compensation and other personnel costs; program expected to remove roughly $100 million of annual costs when complete. Implied workforce base (~500/3%) is consistent with the ~17,900 disclosed total.
2024-10-31restructuringin_progress4002%2023-102025-01-31All three business segments (charges not allocated to segment results)USD 50 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
FY23 Plan initiated in fiscal Q4 2023 (August–October 2023, i.e., the prior fiscal year); announcement_date reflects the quarter-end month. Figures are plan-level/cumulative since inception: approximately 400 regular employees (~2 percent of global workforce) plus consolidation of excess facilities including some site closures. FY2024 restructuring expense was $4 million ($46 million recorded in FY2023; $50 million cumulative since inception). Majority of the workforce reduction completed in FY2024; remaining activities expected substantially complete by end of fiscal Q1 2025 (January 31, 2025). Expected to remove roughly $80 million of annual costs when complete. Not double-counted with prior-year 10-K reporting; captured here as the plan-level figures re-disclosed in this filing.
2024-10-31acquisition_additioncompleted2024-09-202024-09-20Diagnostics and Genomics (expands contract development and manufacturing organization; goodwill allocated to the diagnostics and genomics reporting unit)USD 915 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML
Acquired 100 percent of BIOVECTRA stock for $915 million in cash on September 20, 2024; the $915 million is total purchase consideration, not a workforce charge. Employee headcount added through the acquisition is not disclosed. BIOVECTRA became a wholly-owned subsidiary, expanding Agilent's contract development and manufacturing organization; results consolidated from the acquisition date. Assumed interest-free government loans (Strategic Innovation Fund; Atlantic Canada Opportunities Agency) recorded in short- and long-term debt.
2024-10-31otherannounced2024-112025-01-31Company-wide segment re-organization: diagnostics and genomics combined with liquid chromatography and mass spectrometry platforms into a new 'life sciences and diagnostics markets' segment; chemistries and supplies, laboratory automation and robotics, and software and informatics moved to Agilent CrossLab; remaining divisions (gas chromatography, GC/MS, remarketed instruments, spectroscopy, vacuum) form a new 'applied markets' segmentsubsequent_events
f5-10k / GLM-5.3-flash-HTML
Organizational structure change announced November 2024, creating three new reportable segments effective with first-quarter fiscal 2025 reporting (expected_completion_date reflects the end of fiscal Q1 2025, January 31, 2025). No workforce reduction or headcount impact disclosed; captured as an organizational workforce action since employees move between the redefined segments.
2024-10-31restructuringin_progress5003%2024-05-012025-04-30GlobalAll three business segmentsUSD 72 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Initiated in Q3 FY2024; reduction of approximately 500 regular employees (~3% of global workforce). Expected annual cost savings of ~$100M when complete. Substantially complete by end of Q2 FY2025.
2024-10-31restructuringin_progress4002%2023-08-012025-01-31GlobalAll three business segments; includes facility consolidation and site closuresUSD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY23 Plan initiated in Q4 FY2023; $4M charged in FY2024 (cumulative $50M since inception). Headcount reduction of ~400 (~2% of workforce) plus excess facility consolidation. Expected annual cost savings of ~$80M when complete.
2024-10-31acquisition_additioncompleted2024-09-202024-09-20CanadaDiagnostics and Genomics — advanced manufacturing partnerships (CDMO)USD 915 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquired 100% of BIOVECTRA for $915M cash; headcount added not disclosed. Represents 3% of total assets at year-end.
2024-10-31divestiture_reductioncompleted2023-10-012023-10-31United StatesDiagnostics and Genomics — Resolution BioscienceUSD 43 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Divested in Q4 FY2023 for $50M with $43M gain; headcount removed not disclosed. Prior-year action referenced for context; no FY2024 headcount impact quantified.
2024-10-31restructuringin_progress5003%2024-07-012025-07-31GlobalAll segmentsUSD 72 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY24 Plan initiated in Q3 FY24. Reduction of 500 regular employees (3% of global workforce). Majority completed in FY24; remaining activities expected by end of Q2 FY25.
2024-10-31restructuringin_progress4002%2023-07-012025-01-31GlobalAll segmentsUSD 4 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY23 Plan initiated in Q4 FY23. Reduction of 400 regular employees (2% of global workforce) and consolidation of excess facilities. $4 million expense recorded in FY24. Majority completed in FY24; remaining activities expected by end of Q1 FY25.
2024-10-31restructuringin_progress5003%2024-07-012025-07-31GlobalAll segmentsUSD 72 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
FY24 Plan initiated in Q3 FY24. Reduction of ~500 regular employees (~3% of global workforce). Expected to substantially complete by end of Q2 FY25.
2024-10-31restructuringin_progress4002%2024-01-012025-04-30GlobalAll segmentsUSD 4 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
FY23 Plan initiated in Q4 FY23. Reduction of ~400 regular employees (~2% of global workforce) and consolidation of excess facilities. $4M expense recorded in FY24. Expected to substantially complete by end of Q1 FY25.
2024-10-31restructuringin_progressEmployee Severance [Member]USD 75,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progressFacility Closing [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progressUSD 76,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progressCost of Sales [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progressResearch and Development Expense [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 42,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progressEmployee Severance [Member] / FY24 Restructuring Plan [Member]USD 72,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progressFY23 Restructuring Plan [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progressEmployee Severance [Member] / FY23 Restructuring Plan [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progressFacility Closing [Member] / FY23 Restructuring Plan [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progressSegment Reporting, Reconciling Item, Corporate Nonsegment [Member]USD 76,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-10-31restructuringin_progress500FY24 Restructuring Plan [Member]restructuring_footnote
f5-10k / no-ai-xblr
2024-07-31restructuringin_progress5003%2024-05-012025-04-30GlobalAll three business segmentsUSD 67 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML
FY24 Plan announced in Q3 FY2024; workforce reduction of approximately 500 regular employees (~3% of global workforce). Majority of reduction to be completed by end of FY2024, remaining activities substantially complete by Q2 FY2025. Expected to yield ~$100 million in annual cost reductions. Includes $6 million non-cash accelerated share-based compensation; liability of $42 million at July 31, 2024.
2024-07-31restructuringin_progress4002%2023-08-012024-10-31GlobalAll three business segmentsUSD 50 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML
FY23 Plan initiated in Q4 FY2023; ~400 regular employees (~2% of global workforce) plus consolidation of excess facilities including site closures. Majority of workforce reduction completed in Q1 FY2024; remaining activities substantially complete by end of FY2024. Expected to yield ~$80 million in annual cost reductions. Total expense since inception $50 million; liability of $4 million at July 31, 2024.
2024-07-31restructuringin_progress5003%2025-04-30GlobalAll three business segments (life sciences and applied markets, diagnostics and genomics, Agilent CrossLab)USD 67 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced in Q3 FY2024; exact announcement date not disclosed. Reduction of approximately 500 regular employees (~3% of global workforce); $67M charge recorded in both the three and nine months ended July 31, 2024; $42M liability remaining at quarter-end. Expected to deliver roughly $100M in annual cost savings when complete.
2024-07-31restructuringin_progress4002%2024-10-31GlobalAll three business segments; includes consolidation of excess facilities and site closuresUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Plan initiated in Q4 FY2023 (prior to this quarter); exact announcement date not disclosed. Charge shown is the nine-month FY2024 amount (approximately zero in the three months ended July 31, 2024); total expense since inception is $50M. Remaining activities expected to be substantially complete by end of FY2024; $4M liability remaining at quarter-end.
2024-07-31acquisition_additionannounced2024-07-212024-12-31GlobalContract development and manufacturing organization (BIOVECTRA)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Agreement signed July 21, 2024 to acquire BIOVECTRA for $925 million in cash, subject to customary closing conditions including regulatory approvals; close expected before calendar year 2025. Headcount added through the acquisition is not disclosed.
2024-07-31restructuringin_progress5003%2024-07-312025-04-30GlobalAll segmentsUSD 67 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY24 Plan announced in Q3 FY24. Reduction of ~500 regular employees (~3% of global workforce). Majority of workforce reduction to be completed by end of FY24; remaining activities by Q2 FY25.
2024-07-31restructuringin_progress4002%2023-10-312024-10-31GlobalAll segmentsUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY23 Plan initiated in Q4 FY23. Reduction of ~400 regular employees (~2% of global workforce) and consolidation of excess facilities. Majority of workforce reduction completed in Q1 FY24; remaining activities expected to be substantially complete by end of FY24.
2024-07-31restructuringin_progressEmployee Severance [Member]USD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-31restructuringin_progressFacility Closing [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-31restructuringin_progressUSD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-31restructuringin_progressCost of Sales [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-31restructuringin_progressResearch and Development Expense [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-31restructuringin_progress500FY24 Restructuring Plan [Member]USD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-31restructuringin_progressEmployee Severance [Member] / FY24 Restructuring Plan [Member]USD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-31restructuringin_progressFY23 Restructuring Plan [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-31restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-04-30restructuringin_progress4002%2023-11-012024-10-31All three business segmentsUSD 50 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML
FY23 Plan initiated Q4 FY2023; ~400 regular employees (~2% of workforce) plus excess facility consolidation including site closures. $50 million cumulative since inception; $1 million in Q2 and $4 million in six months ended April 30, 2024. Majority of workforce reduction completed in Q1 FY2024; remaining activities expected substantially complete by end of FY2024. Expected to reduce annual cost of sales and operating expenses by $80 million.
2024-04-30restructuringannounced5003%2024-05-292024-10-31USD 55 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML
FY24 Plan announced May 29, 2024; reduction of approximately 500 regular employees (~3% of global workforce). Costs include severance and other personnel costs, estimated at approximately $55 million. Expected to reduce annual cost of sales and operating expenses by approximately $100 million; most activities to be completed by end of fiscal year 2024.
2024-04-30restructuringin_progress4002%2024-10-31GlobalAll three business segmentsUSD 50 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Initiated in Q4 FY2023 (exact announcement date not disclosed in this filing); reduction of approximately 400 regular employees (~2% of global workforce) plus consolidation of excess facilities including site closures. $50M recorded since inception, of which $4M in the six months and $1M in the three months ended April 30, 2024; $6M accrual remaining at April 30, 2024. Implied total (400 / 2%) is broadly consistent with disclosed headcount of ~17,600.
2024-04-30restructuringannounced5003%2024-05-292024-10-31GlobalAll business segmentsUSD 55 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced May 29, 2024, after the April 30, 2024 quarter close; reduction of approximately 500 regular employees (~3% of global workforce), estimated cost approximately $55M, mostly to be completed by end of fiscal year 2024. Implied total (500 / 3%) is broadly consistent with disclosed headcount of ~17,600.
2024-04-30restructuringin_progress4002%2023-10-312024-10-31GlobalAll segmentsUSD 50 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY23 Plan initiated in Q4 FY23. Includes headcount reduction and facility consolidation. Total costs since inception $50 million. Majority of workforce reduction completed in Q1 FY24.
2024-04-30restructuringannounced5003%2024-05-292024-10-31GlobalAll segmentsUSD 55 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0
FY24 Plan announced May 29, 2024. Includes headcount reduction of approx 500 regular employees. Estimated costs $55 million.
2024-04-30restructuringin_progressUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-04-30restructuringin_progressEmployee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-04-30restructuringin_progressFacility Closing [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-04-30restructuringin_progressCost of Sales [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-04-30restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-04-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-04-30restructuringin_progressSegment Reconciling Items [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-31restructuringin_progress4002%2024-10-31GlobalAll three business segments (costs not allocated to segments)USD 49 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY23 Plan initiated in Q4 FY2023 (exact announcement date not disclosed); covers ~400 regular employees (~2% of global workforce) plus consolidation of excess facilities including site closures. $3M charged in Q1 FY2024; $49M cumulative since inception; $11M accrual at 2024-01-31. Majority of workforce reduction completed in Q1 FY2024; expected annual cost savings of $80M.
2024-01-31restructuringin_progress4002%2023-10-312024-10-31GlobalAll segmentsUSD 49 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY23 Plan initiated in Q4 FY23 to reduce headcount by approx. 400 regular employees (approx. 2% of global workforce) and consolidate excess facilities. Total costs recorded since inception are $49 million. Majority of workforce reduction completed in Q1 FY24; remaining activities expected to substantially complete by end of FY24.
2024-01-31restructuringin_progress400USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-31restructuringin_progressEmployee Severance [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-31restructuringin_progressFacility Closing [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-31restructuringin_progressCost of Sales [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-31restructuringin_progressResearch and Development Expense [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-31restructuringin_progressSegment Reconciling Items [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-31restructuringin_progress4002%2024-10-31All three business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, Agilent CrossLabUSD 46 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
FY23 Plan initiated in Q4 fiscal 2023 (August-October 2023); no specific announcement date disclosed. Reduction is approximately 400 regular employees (~2% of global workforce per filer; 400 of ~18,100 is roughly 2.2%, filer rounds down). FY2023 charges of ~$46 million comprise $33M workforce reduction expense and $13M excess-facilities consolidation (including $8M accelerated depreciation of right-of-use and machinery/equipment assets), partially offset by $1M accelerated share-based compensation credit; $36M accrual remained at October 31, 2023, recorded in other accrued liabilities, plus some site closures. Majority of workforce reduction expected complete in Q1 fiscal 2024; remaining activities substantially complete by end of fiscal 2024. Program expected to yield $80 million in annual cost-of-sales and operating-expense reductions once completed. Restructuring costs were not allocated to segment results.
2023-10-31restructuringin_progress4002%2023-07-312023-10-31GlobalAll three business segmentsUSD 46 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Initiated in Q4 FY2023; reduction of approximately 400 regular employees (~2% of global workforce) plus consolidation of excess facilities and site closures. Majority of workforce reduction expected to complete in Q1 2024, with remaining activities substantially complete by end of FY2024; expected annual cost savings of $80 million. Announcement date approximated to start of Q4 FY2023 (Aug 1, 2023) as no exact date is given; expected_completion_date reflects the majority-reduction milestone.
2023-10-31divestiture_reductioncompleted2023-04-302023-10-31United StatesDiagnostics and Genomics — Resolution BioscienceUSD 270 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Exit decision made in Q3 FY2023 with a $270 million long-lived asset impairment charge; business divested in Q4 FY2023 for $50 million with a $43 million gain. Headcount associated with the business not disclosed. Announcement date approximated to end of Q3 FY2023 (Jul 31, 2023).
2023-10-31acquisition_additioncompletedDiagnostics and Genomics; Life Sciences and Applied MarketsUSD 51 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Two businesses acquired during FY2023 for a total purchase price of $51 million; acquired headcount not disclosed.
2023-10-31restructuringin_progress4002%2023-10-012024-10-31GlobalAll segmentsUSD 46 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY23 Plan initiated in Q4 FY23. Includes workforce reduction of approx 400 regular employees (2% of global workforce) and consolidation of excess facilities. Total costs recorded in FY23 were $46 million. Majority of workforce reduction expected to complete in Q1 FY24; remaining activities by end of FY24.
2023-10-31restructuringin_progress4002%2023-10-312024-10-31GlobalAll segmentsUSD 46 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
FY23 Plan initiated in Q4 FY23. Includes workforce reduction of approx 400 regular employees (2% of global workforce) and consolidation of excess facilities. Majority of workforce reduction expected to complete in Q1 FY24; remaining activities by end of FY24.
2023-10-31restructuringin_progress400USD 46,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-10-31restructuringin_progressEmployee Severance [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-10-31restructuringin_progressFacility Closing [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-10-31restructuringin_progressCost of Sales [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-10-31restructuringin_progressResearch and Development Expense [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-10-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-10-31restructuringin_progressCorporate, Non-Segment [Member]USD 46,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-07-31restructuringin_progressDiagnostics and GenomicsUSD 277 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Decision made during the quarter to shut down the Resolution Bioscience business; charge is a long-lived asset impairment written down to zero, not severance. Note 1 states a $270 million long-lived asset impairment while Note 9, the cash flow statement and the segment reconciliation show $277 million. No employee count, announcement date or completion date disclosed.
2023-07-31restructuringcompleted2023-07-31Diagnostics and GenomicsUSD 270 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0
Shutdown of Resolution Bioscience business resulted in $270 million long-lived asset impairment charge. Employee count not disclosed.
2023-01-31acquisition_additioncompletedDiagnostics and GenomicsUSD 30 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Avida Biomed completed during the quarter (cash outflow of $30 million); added $11 million goodwill and $23 million intangibles in the diagnostics and genomics segment. Headcount added through the acquisition was not disclosed.
2022-10-31othercompleted2022-05-232022-05-23RussiaMD&A
f5-10k / GLM-5.3-flash-HTML
Country exit: after suspending sanctioned sales and halting most product shipments to Russia in March 2022, the company ceased major operations within Russia effective May 23, 2022. The in-country workforce was wound down as part of the shutdown, but the affected headcount is not quantified. An immaterial shutdown-related expense was recorded for the three months ended April 30, 2022, and Russia-derived sales were an immaterial share of total revenue.
2022-04-30acquisition_additioncompleted2022-02Diagnostics and Genomics (implied by intangible asset context)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of advanced AI technology completed in February 2022; $21M of intangibles recorded and contingent consideration added, but no headcount added was disclosed.
2022-04-30otherannounced2022-05-232022-05-23RussiaAll functions (Russia operations)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Sanctions-related suspension of sales began early March 2022; total cessation of Russia operations effective May 23, 2022 (post-quarter). Immaterial shutdown expense recorded in Q2 FY2022; no affected-employee count disclosed.
2021-10-31acquisition_additioncompleted2021-04-15Diagnostics and Genomicsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML
Acquired privately-held Resolution Bioscience, Inc. on April 15, 2021 for $561 million cash plus contingent payments of up to $145 million tied to revenue and technical milestones; adds NGS-based precision oncology capabilities. Employee headcount acquired was not disclosed.
2021-10-31restructuringin_progressUSD 37 (millions)other
f5-10k / GLM-5.3-flash-HTML
Ongoing transformational initiatives program encompassing targeted cost-reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, and in-sourcing/outsourcing. $37 million charged in fiscal 2021; no affected-employee headcount or completion timeline disclosed. Risk factors separately reference ongoing reorganizations, workforce reductions and site closures, and the segment reconciliation shows $1 million of accelerated share-based compensation from workforce reductions.
2021-10-31acquisition_additioncompleted2021-04-152021-04-15United StatesDiagnostics and genomicsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Resolution Bioscience completed 2021-04-15 for $561M cash plus up to $145M contingent; headcount added not disclosed
2021-07-31acquisition_additioncompleted2021-04-152021-04-15Diagnostics and Genomicsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Resolution Bioscience for $550 million cash plus up to $145 million contingent payments; headcount added not disclosed. Goodwill of $365 million recorded in the Diagnostics and Genomics segment.
2021-04-30acquisition_additioncompleted2021-04-152021-04-15United StatesDiagnostics and Genomicsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Resolution Bioscience completed April 15, 2021 for $550M cash plus up to $145M contingent payments; headcount added not disclosed.
2021-01-31acquisition_additionannounced2021-03-012021-04-30United StatesDiagnostics and Genomicssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Agreement signed March 1, 2021 to acquire Resolution Bioscience for $550 million cash plus up to $145 million contingent payments; expected to close in Q2 FY2021. Headcount added not disclosed.
2020-10-31restructuringin_progressUSD 53 (millions)other
f5-10k / GLM-5.3-flash-HTML
Multi-year program of targeted cost-reduction activities (manufacturing transfers, site consolidations, business reorganizations, in-/outsourcing); only the FY2020 charge of $53M is captured — comparative prior-year charges excluded. No affected-employee count, announcement date, or completion date disclosed.
2020-10-31reduction_in_forcecompletedUSD 2 (millions)other
f5-10k / GLM-5.3-flash-HTML
Disclosed only as accelerated share-based compensation expense related to a workforce reduction during FY2020; affected headcount and timing details not disclosed.
2020-10-31restructuringin_progressEnterprise-wideUSD 2 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY2020 segment reconciliation includes a $2M line for accelerated share-based compensation related to a workforce reduction; no headcount, date, or geography disclosed. Separate transformational initiatives charges of $53M in FY2020 cover cost-reduction activities (manufacturing transfers, site consolidations, reorganizations) without stated employee counts.
2020-07-31restructuringcompletedGlobalDiagnostics and Genomics — sequencer development programUSD 99 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Shut-down of the sequencer development program recorded during the nine months ended July 31, 2020; $90M in-process R&D impairment plus long-lived assets written down to zero ($98M carrying amount), $99M total asset impairment per cash flow statement. No employee count, severance amount, or announcement date disclosed.
2019-10-31acquisition_additioncompleted2018-11-14Life Sciences and Applied Marketsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML
ACEA Biosciences Inc., a developer of cell analysis tools, acquired for $250 million; November 14, 2018 shown is the completion date (falls in fiscal 2019 for this October year-end filer). No employee headcount added through the deal is disclosed.
2019-10-31acquisition_additioncompleted2019-08-23United States (Vermont)Life Sciences and Applied Marketsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML
Privately held Lionheart Technologies LLC (BioTek), a life science instrumentation maker, acquired for $1.17 billion, funded with $470 million cash and $700 million debt; date shown is the completion date. Filing cites intent to utilize the assembled workforce but discloses no headcount; Vermont organization per Exhibit 21.1.
2019-10-31acquisition_additioncompleted2019-08-232019-08-23United StatesLife Sciences and Applied MarketsUSD 1,170 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Lionheart Technologies LLC (BioTek), funded with $470M cash and $700M debt; acquired headcount not disclosed.
2019-10-31acquisition_additioncompleted2018-11-142018-11-14United StatesLife Sciences and Applied MarketsUSD 250 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition completed early in fiscal 2019 (Nov 14, 2018); acquired headcount not disclosed.
2019-10-31restructuringcompleted2019-10-31GlobalCorporateUSD 44 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Transformational initiatives include manufacturing transfers, site consolidations, and business reorganizations; employee-affected counts not disclosed. Prior year charge was $25 million.
2019-10-31acquisition_additioncompleted2019-08-23GlobalLife Sciences and Applied MarketsUSD 1,170 (millions)Item 1. Business; Note 3. Acquisitions
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Completed acquisition of Lionheart Technologies LLC (BioTek) for $1.17 billion. Headcount not explicitly disclosed.
2019-10-31acquisition_additioncompleted2018-11-14GlobalLife Sciences and Applied MarketsUSD 250 (millions)Item 1. Business; Note 3. Acquisitions
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Acquired 100% of ACEA Biosciences for $250 million. Headcount not explicitly disclosed.
2019-07-31acquisition_additioncompleted2018-11-142018-11-14Life Sciences and Applied MarketsUSD 250 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Closed in Q1 of fiscal 2019 (prior quarter of the same fiscal year); purchase price disclosed, no employee count disclosed. Goodwill additions of $153 million in the nine months relate primarily to this acquisition.
2019-07-31acquisition_additioncompleted2019-08-232019-08-23USD 1,165 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter event; date shown is the completion date. Purchase price disclosed, no employee count disclosed. Funded in part by a $500 million short-term loan facility drawn in full; results included from the close in Q4 fiscal 2019.
2019-04-30acquisition_additioncompleted2018-11-14Life Sciences and Applied Marketsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
100% stock acquisition of ACEA Biosciences for approximately $250 million cash; headcount added not disclosed
2019-01-31acquisition_additioncompleted2018-11-142018-11-14United StatesLife Sciences and Applied MarketsUSD 250 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquired 100% of ACEA Biosciences, a cell analysis tools developer, for approximately $250 million in cash; headcount added not disclosed. Purchase accounting substantially complete, to be finalized during 2019.
2018-10-31restructuringin_progressUSD 25 (millions)other
f5-10k / GLM-5.3-flash-HTML
Multi-year cost-reduction program covering manufacturing transfers, site consolidations, legal-entity/business reorganizations and in-/outsourcing. FY2018 charge was $25 million (vs $12 million in FY2017). No headcount, announcement date, or completion date disclosed; program status not explicitly stated.
2018-10-31otherin_progressPrimarily the NMR businessUSD 9 (millions)other
f5-10k / GLM-5.3-flash-HTML
Business exit and divestiture costs of $9 million recognized in FY2018, primarily related to the NMR business. No headcount, timeline, or program status disclosed; recorded as 'other' because the filing does not describe a sale, spin-off, or headcount reduction.
2018-10-31acquisition_additioncompletedUSD 536 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML
Seven businesses acquired during FY2018 for combined purchase price of approximately $536 million; largest was Advanced Analytical Technologies, Inc. for approximately $268 million in cash. Headcount added was not disclosed; filer states the acquisitions were not material individually or in aggregate. Acquisitions spanned multiple segments (e.g., Lasergen and AATI in Diagnostics and Genomics; Ultra Scientific and ProZyme in Agilent CrossLab).
2018-10-31acquisition_additioncompletedUSD 250 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML
100 percent of ACEA Biosciences Inc., a developer of cell analysis tools, acquired on November 14, 2018 (after fiscal year-end) for approximately $250 million in cash; results included from the close date. Headcount not disclosed.
2018-10-31acquisition_additioncompletedGlobalMultiple (largest: Advanced Analytical Technologies, Inc.)USD 536 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Seven businesses acquired during fiscal 2018 for a combined purchase price of approximately $536 million; largest was AATI at approximately $268 million in cash. No headcount added disclosed
2018-10-31acquisition_additioncompletedUnited StatesDiagnostics and Genomics (genomics)USD 107 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Exercise of option to acquire all remaining shares of Lasergen, Inc. during fiscal 2018 for approximately $107 million cash, on top of an $80 million preferred investment made in fiscal 2016; no headcount disclosed
2018-10-31acquisition_additioncompleted2018-11-142018-11-14United StatesLife Sciences and Applied Markets (cell analysis)USD 250 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of 100% of ACEA Biosciences Inc. closed after fiscal year-end; results included from close date; no headcount disclosed
2018-10-31restructuringin_progressGlobalEnterprise (transformational initiatives)USD 25 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Transformational initiatives charge of $25 million recorded in fiscal 2018 (versus $12 million in fiscal 2017); covers manufacturing transfers, site consolidations and business reorganizations. No employee counts or restructuring footnote disclosed
2018-10-31divestiture_reductionin_progressGlobalNMR businessUSD 9 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Business exit and divestiture costs of $9 million in fiscal 2018, primarily related to the NMR business; no headcount impact disclosed
2018-10-31acquisition_additioncompleted2018-11-14GlobalDiagnostics and GenomicsUSD 250 (millions)subsequent_events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences Inc. for approximately $250 million in cash. Headcount not disclosed.
2018-10-31acquisition_additioncompleted2018-10-31GlobalVariousUSD 536 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
In 2018, we acquired seven businesses, for a combined purchase price of approximately $536 million. The largest was Advanced Analytical Technologies, Inc. for approximately $268 million. Headcount not disclosed.
2018-07-31acquisition_additioncompleted2018-05-072018-05-07United StatesDiagnostics and GenomicsUSD 107 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquired remaining shares of Lasergen for approximately $107 million cash; acquired headcount not disclosed.
2018-07-31acquisition_additioncompleted2018-05-142018-05-14SwitzerlandAgilent CrossLabUSD 41 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquired 100% of Genohm SA, a lab informatics company, for approximately $41 million cash; acquired headcount not disclosed.
2018-07-31acquisition_additioncompleted2018-05-312018-05-31United StatesDiagnostics and GenomicsUSD 269 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquired 100% of Advanced Analytical Technologies for approximately $269 million cash; acquired headcount not disclosed.
2018-07-31acquisition_additioncompleted2018-07-162018-07-16United StatesAgilent CrossLabUSD 32 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquired substantially all assets and liabilities of Ultra Scientific for $32 million cash, plus a $3 million contingent payment treated as post-acquisition compensation; acquired headcount not disclosed.
2018-07-31acquisition_additionannounced2018-08-012018-08-01United StatesAgilent CrossLabsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter acquisition of ProZyme, a glycan analysis reagents provider; combined cash for this and the Young In Scientific acquisition was approximately $80 million; acquired headcount not disclosed.
2018-07-31acquisition_additionannounced2018-08-172018-08-17South KoreaAgilent CrossLabsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter acquisition of certain assets from Young In Scientific, an analytical instrument distributor; acquired headcount not disclosed.
2018-04-30acquisition_additioncompleted2018-05-07USD 105 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Option exercised and merger agreement signed during the quarter to buy the remaining Lasergen, Inc. shares not already owned (48% initial stake); additional cash consideration $105 million. Acquisition completed 2018-05-07. No headcount added disclosed.
2018-04-30acquisition_additioncompleted2018-03-072018-05-31United StatesUSD 250 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Merger agreement for Advanced Analytical Technologies, Inc. (Ankeny, Iowa), $250 million cash subject to purchase price adjustments; completed 2018-05-31. No headcount added disclosed.
2018-04-30acquisition_additioncompleted2018-05-14SwitzerlandUSD 40 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquired 100% of Genohm SA, a lab informatics company, for approximately $40 million cash; completed 2018-05-14 (post-quarter). No headcount added disclosed.
2018-04-30acquisition_additionannounced2018-05-23South Koreasubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Agreement signed to acquire certain assets of Young In Scientific Co. Ltd., a distributor of analytical instruments; closing expected during fiscal Q4 2018 (cash consideration part of approximately $60 million combined with Ultra Scientific). No headcount disclosed.
2018-04-30acquisition_additionannounced2018-05-25subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Agreement signed to acquire substantially all assets and liabilities of Ultra Scientific Incorporated; closing expected during fiscal Q3 2018 (cash consideration part of approximately $60 million combined with Young In Scientific). No headcount disclosed.
2018-04-30restructuringin_progressEnterprise-wideUSD 9 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Transformational initiatives expense of $9 million for the six months ended April 30, 2018 ($5 million in the quarter); described as targeted cost reduction activities including manufacturing transfers, site consolidations and business reorganizations. No employee counts, severance detail or completion dates disclosed.
2018-01-31acquisition_additioncompletedDiagnostics and GenomicsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition closed during the quarter (goodwill addition of $5 million disclosed in Note 7); no headcount added disclosed. Related incremental R&D and SG&A spend noted in segment discussion.
2018-01-31acquisition_additionannounced2018-02-23USD 105 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter event; completion contingent on merger agreement and closing conditions. No workforce impact disclosed; Agilent already held a 48 percent stake.
2017-10-31acquisition_additioncompleted2017-01-20BelgiumDiagnostics and GenomicsMD&A
f5-10k / GLM-5.3-flash-HTML
Completed acquisition of 100% of Multiplicom NV, a Belgian molecular diagnostics company, for approximately $72 million in cash; disclosed date is the acquisition completion date. Employee count added not disclosed. Note 9 shows fiscal 2017 goodwill additions of $52 million in Diagnostics and Genomics consistent with this deal.
2017-10-31acquisition_additioncompleted2017-07-07United KingdomLife Sciences and Applied MarketsMD&A
f5-10k / GLM-5.3-flash-HTML
Completed acquisition of Cobalt Light Systems, an Oxfordshire-based Raman spectroscopy provider, for approximately $53 million in cash; disclosed date is the acquisition completion date. Employee count added not disclosed. Note 9 shows fiscal 2017 goodwill additions of $26 million in Life Sciences and Applied Markets consistent with this deal.
2017-10-31acquisition_additioncompleted2017-01-202017-01-20Belgium (Europe)Diagnostics and GenomicsUSD 72 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of 100% of Multiplicom NV completed January 20, 2017 for approximately $72 million in cash; acquired headcount not disclosed.
2017-10-31acquisition_additioncompleted2017-07-072017-07-07United KingdomLife Sciences and Applied MarketsUSD 53 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Cobalt Light Systems completed July 7, 2017 for approximately $53 million in cash; acquired headcount not disclosed.
2017-07-31acquisition_additioncompleted2017-01-20Belgium (Europe)Diagnostics and GenomicsUSD 72 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Purchase price approximately $72 million in cash; acquired headcount not disclosed in filing
2017-07-31acquisition_additioncompleted2017-07-07United Kingdom (Oxfordshire)Life Sciences and Applied MarketsUSD 53 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Purchase price approximately $53 million in cash; acquired headcount not disclosed in filing
2017-04-30acquisition_additioncompleted2017-01-20Europe (Belgium headquarters)Diagnostics and GenomicsUSD 72 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Purchase price approximately $72 million in cash; acquired headcount not disclosed in this filing
2017-04-30acquisition_additioncompletedAgilent CrossLabMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
MD&A attributes R&D and SG&A expense increases partly to headcount growth from the iLab acquisition; acquisition date and added headcount not disclosed in this filing
2017-01-31acquisition_additioncompleted2017-01-20Belgium (Europe)Diagnostics and GenomicsUSD 72 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Multiplicom NV completed January 20, 2017 for approximately $72 million in cash; acquired headcount not disclosed. Purchase accounting preliminary.
2016-10-31restructuringcompleted20142016-10-31Life Sciences and Applied Markets (NMR product line)other
f5-10k / GLM-5.3-flash-HTML
Multi-year business exit: decision to cease the NMR product line made in Q4 FY2014; restructuring and related charges of roughly $68M (FY2014) and $6M (FY2015) recorded; exit completed during FY2016. Employee impact not disclosed. FY2016 segment reconciliation shows $11M of restructuring and business exit related costs in total.
2016-10-31acquisition_additioncompleted2015-112015-11Cell metabolism / bioenergetics instruments and assay kitsUSD 242 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML
Acquisition of Seahorse Bioscience completed for $242M cash; results consolidated into Agilent from November 1, 2015 (start of FY2016). Headcount added through the acquisition not disclosed.
2016-10-31acquisition_additioncompleted2016-08-012016-08-01Cloud-based core laboratory management softwareUSD 26 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML
Acquisition of substantially all assets of iLab Solutions LLC completed August 1, 2016 for $26M cash; results consolidated from that date. Headcount added not disclosed.
2016-10-31acquisition_additionannounced2016-12-192017-01BelgiumMolecular diagnostics (genetic testing assays)EUR 68 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML
Agreement signed December 19, 2016 to acquire 100% of the stock of Multiplicom NV for approximately €68M cash; closing expected mid-January 2017 (fiscal Q1 2017), subject to local laws and customary conditions. Headcount not disclosed.
2016-10-31restructuringcompleted2014-10-312016-10-31GlobalLife Sciences and Applied Markets (NMR product line)USD 11 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Exit of the nuclear magnetic resonance business announced in Q4 FY2014 and completed during fiscal 2016; $11M is total restructuring and business exit related costs for FY2016, not NMR-specific. Employees affected not disclosed.
2016-10-31acquisition_additioncompleted2015-11-012015-11-01United StatesLife Sciences and Applied Markets (cell metabolism / bioenergetics instruments)USD 242 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Seahorse Bioscience acquired for $242M cash; results consolidated from November 1, 2015. Headcount added not disclosed; value shown is purchase price.
2016-10-31acquisition_additioncompleted2016-08-012016-08-01United StatesAgilent CrossLab (cloud-based core lab management software)USD 26 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Substantially all assets of iLab Solutions LLC acquired for $26M cash. Headcount added not disclosed; value shown is purchase price.
2016-10-31acquisition_additionannounced2016-12-192017-01-15Belgium / EuropeDiagnostics and Genomics (molecular diagnostic assays)EUR 68 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Agreement signed to acquire 100% of Multiplicom NV for approximately EUR 68 million in cash; expected close mid-January 2017. Headcount added not disclosed; value shown is purchase price.
2016-10-31restructuringcompleted2014-10-012016-10-31GlobalLife Sciences and Applied MarketsUSD 6 (millions)Item 1. Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Exit of NMR business completed in fiscal 2016. $6 million in restructuring and other related costs recorded in 2015; $68 million recorded in 2014. Employee count not explicitly disclosed for this action.
2016-10-31restructuringcompleted2014-10-312016-10-31GlobalLife Sciences and Applied MarketsUSD 6 (millions)Item 1. Business - Exit of Nuclear Magnetic Resonance Business
f5-10k / Qwen3.6-27B-Q8_0
Exit of NMR business completed in fiscal 2016. $6 million in restructuring and other related costs recorded in 2015; $68 million recorded in 2014. Employee count not specified.
2016-10-31restructuringcompletedGlobalGlobalItem 1. Business - Research and Development
f5-10k / Qwen3.6-27B-Q8_0
Announced workforce reduction plan resulted in acceleration of share-based compensation. Incremental expense of $0 million in 2016. Employee count not specified.
2016-07-31acquisition_additioncompleted2015-11-012015-11-01Life Sciences and Applied Marketsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Seahorse Bioscience for $242 million in cash, completed November 1, 2015; added $137 million of goodwill to the Life Sciences and Applied Markets segment. Headcount added not disclosed.
2016-07-31divestiture_reductionin_progressNMR businessUSD 7 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Charge shown is the nine-month total ($1 million in the three months ended July 31, 2016). Filer attributes gross margin and revenue improvements to the NMR exit; no employee count, announcement date or completion date disclosed.
2016-07-31acquisition_additioncompleted2016-08-012016-08-01subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter acquisition of substantially all assets of iLab Solutions LLC for $26 million in cash; purchase price allocation not yet complete and results included from Q4 FY2016. Headcount added not disclosed.
2016-04-30acquisition_additioncompleted2015-11-01Life Sciences and Applied MarketsUSD 242 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Seahorse Bioscience completed November 1, 2015 for $242 million; no employee headcount added through the acquisition is disclosed in this filing.
2016-01-31acquisition_additioncompleted2015-11-01Life Sciences and Applied Marketsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Seahorse Bioscience acquired for $242 million; no employee headcount disclosed.
2016-01-31divestiture_reductionin_progressLife Sciences and Applied Markets (NMR business)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Company exiting NMR business; no affected-employee count disclosed.
2016-01-31restructuringcompleted2016-04-30United StatesCorporate / All SegmentsUSD -16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Freeze of benefit accruals under U.S. Retirement Plan and Supplemental Benefits Retirement Plan effective April 30, 2016. Recorded $15 million curtailment gain and $1 million settlement gain.
2016-01-31acquisition_additioncompleted2015-11-01Life Sciences and Applied MarketsUSD 242 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0
Acquisition of Seahorse Bioscience for $242 million. Headcount not explicitly disclosed.
2015-10-31restructuringin_progress30020142016Primarily United Kingdom and California, United StatesLife Sciences and Applied Markets (NMR product line)USD 6 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Multi-year program: decision taken in Q4 FY2014 (quarter ended October 31, 2014) to cease manufacture and sale of the nuclear magnetic resonance product line, entailing severance for roughly 300 employees plus intangible impairments, asset write-downs and inventory charges. After attrition and internal redeployment, approximately 30 employees remained pending termination as of October 31, 2015. FY2015 expense of $6 million followed $68 million recorded in FY2014; approximately $15 million paid to date under the program and an $8 million restructuring accrual (recorded in other accrued liabilities) remained at fiscal year-end. Filer expects completion by early fiscal 2016.
2015-10-31restructuringin_progress3002014-102016-01-31Primarily United Kingdom and CaliforniaLife Sciences and Applied Markets — NMR product lineUSD 6 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Cumulative through fiscal year-end: ~300 employees affected since announcement in Q4 FY2014. FY2015 charge was $6M (FY2014 charge was $68M). Approximately 30 employees still pending termination as of 2015-10-31; expected completion early fiscal 2016. Approximately $15M paid to date under these restructuring activities.
2015-10-31divestiture_reductioncompleted2013-09-192014-11-01GlobalElectronic Measurement business (Keysight Technologies)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Spin-off of Keysight Technologies completed 2014-11-01 (first day of FY2015). Keysight headcount not disclosed in this filing. Keysight results reported as discontinued operations.
2015-10-31acquisition_additioncompleted2015-05-192015-05-19EuropeDiagnostics and Genomics — clinical genetics softwareMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Cartagenia for €60 million; headcount added not disclosed.
2015-10-31divestiture_reductioncompleted2015-04-302015-04-30GlobalLife Sciences and Applied Markets — X-ray diffraction (XRD) businessMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Sale of XRD business to Rigaku; no material impact on results stated. Headcount removed not disclosed.
2015-10-31acquisition_additioncompleted2015-11-022015-11-02United StatesLife Sciences and Applied Markets — cell metabolism and bioenergetics instrumentsUSD 242 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Seahorse Bioscience for $242M cash, completed 2015-11-02 (one day after fiscal year-end). Headcount added not disclosed. Results to be included from Q1 FY2016.
2015-10-31restructuringin_progress3002014-10-312016-04-30United Kingdom and CaliforniaLife Sciences and Applied Markets (NMR Business)USD 6 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Workforce reduction of approximately 300 employees primarily located in the UK and California. $6 million in restructuring and other related costs recorded in 2015. Approximately 30 employees pending termination as of Oct 31, 2015. Expected completion by early fiscal 2016.
2015-10-31acquisition_additioncompleted2015-11-022015-11-02GlobalLife Sciences and Applied MarketsUSD 242 (millions)subsequent_events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Acquisition of Seahorse Bioscience completed Nov 2, 2015 for $242 million in cash. Headcount not explicitly disclosed.
2015-10-31acquisition_additioncompleted2015-05-192015-05-19GlobalDiagnostics and GenomicsEUR 60 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Acquisition of Cartagenia completed May 19, 2015 for €60 million. Headcount not explicitly disclosed.
2015-10-31restructuringin_progress3002014-10-312016-04-30United Kingdom and CaliforniaLife Sciences and Applied MarketsUSD 6 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
Exit of NMR business announced in Q4 FY2014. Workforce reduction of approx 300 employees. Approx 30 employees pending termination as of FY2015 year-end. Expected completion early FY2016. FY2015 charge of $6 million.
2015-10-31restructuringin_progressUSD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-10-31restructuringin_progressResearch and Development Expense [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-10-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-10-31restructuringin_progressAsset impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-10-31restructuringin_progressOther Restructuring [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-10-31restructuringin_progressNMR [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-07-31restructuringin_progress3002016-01-31United Kingdom and California (primarily)Life Sciences and Applied Markets (NMR product line)USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Decision to cease NMR manufacture and sale made in Q4 fiscal 2014; exact announcement date not disclosed. Approximately 300 employees in the workforce reduction; approximately 60 pending termination as of 2015-07-31. Charge figure is the restructuring/special accrual balance at 2015-07-31, equal to nine-month income statement expense. Expected completion by early fiscal 2016.
2015-07-31acquisition_additioncompleted2015-05-192015-05-19Diagnostics and Genomicsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Cartagenia (clinical genetics/molecular pathology software) completed for EUR 60 million; no headcount added disclosed.
2015-07-31restructuringin_progress3002014-10-312016-01-31United Kingdom and CaliforniaLife Sciences and Applied Markets (NMR Business)USD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Workforce reduction of approx. 300 employees announced in Q4 FY2014. Approx. 60 employees pending termination as of July 31, 2015. Expected completion early FY2016. Remaining accrual of $9 million.
2015-07-31restructuringin_progress300restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2015-04-30restructuringin_progress30020142016-10-31United Kingdom and CaliforniaLife sciences and applied markets (NMR product line)USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Decision to cease NMR manufacture and sale made in fiscal Q4 2014; approximately 300 employees in the workforce reduction. Approximately 180 employees still pending termination at April 30, 2015; about $9 million paid to date; restructuring and other special accruals totaled $14 million at April 30, 2015. Charge shown is income-statement expense for the six months ended April 30, 2015. Announcement date known only to fiscal-quarter precision.
2015-04-30divestiture_reductioncompleted2013-09-192014-11-01GlobalElectronic measurement business (Keysight Technologies)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Spin-off of Keysight completed November 1, 2014 (fiscal 2015 first quarter); Keysight employees are no longer in Agilent's continuing-operations headcount. No employee count for the transferred workforce is disclosed in this filing.
2015-04-30restructuringin_progress3002014-10-312016-10-31United Kingdom and CaliforniaLife Sciences and Applied MarketsUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Workforce reduction of approximately 300 employees primarily located in the United Kingdom and California. As of April 30, 2015, approximately 180 employees are pending termination. Total restructuring accrual balance was $14 million.
2015-04-30restructuringin_progress300USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2015-04-30restructuringin_progressEmployee Severance [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-04-30restructuringin_progressOther Restructuring [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-01-31restructuringin_progress3002016-10-31United Kingdom and CaliforniaLife Sciences and Applied MarketsUSD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Program covers workforce reduction of approximately 300 employees on exit of the NMR product line; about 200 employees still pending termination at 2015-01-31. Charge shown is the accrual balance at 2015-01-31 ($12M workforce reduction plus $4M inventory/other special charges); $3M was expensed in the quarter. Decision made in Q4 fiscal 2014; no specific announcement date disclosed.
2015-01-31divestiture_reductioncompleted2013-09-192014-11-01GlobalElectronic measurement business (Keysight Technologies)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Spin-off of Keysight completed 2014-11-01; Keysight assets, liabilities and results removed from continuing operations. No headcount transferred with the separation is disclosed in this filing.
2015-01-31restructuringin_progress3002014-10-312016-10-31United Kingdom and CaliforniaLife Sciences and Applied MarketsUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Workforce reduction of approx. 300 employees due to exit of NMR product line. Approx. 200 employees pending termination as of Jan 31, 2015. Total accrual balance $16 million.
2015-01-31restructuringin_progressEmployee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-01-31restructuringin_progressOther Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-01-31restructuringin_progress300USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2014-10-31restructuringin_progress30020142016-10-31Primarily the United Kingdom and California, United StatesLife Sciences and Diagnostics segment — Nuclear Magnetic Resonance (NMR) product lineUSD 68 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Announced in fiscal Q4 2014; company ceased taking new NMR system orders due to lack of growth and profitability. Charges comprise severance/personnel costs for roughly 300 employees plus non-cash intangible impairments and inventory write-downs; jobs to be eliminated mostly within about 12 months, with restructuring substantially complete by end of fiscal 2016. At October 31, 2014 substantially all affected employees were pending termination, ~$2 million paid, and a $17 million accrual remained. Exit expected to improve fiscal 2015 operating profit by roughly $10 million.
2014-10-31restructuringin_progress4002%20132015-01-31United States (substantially complete) and international locationsAll three reportable segments (life sciences and diagnostics, chemical analysis, electronic measurement)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Multi-year program accrued in fiscal Q2 2013 for about 450 regular employees, described as roughly 2 percent of the global workforce at announcement; about 50 redeployed within the company, reducing the plan to about 400. Figures are cumulative program totals. Fiscal 2014 included a $4 million charge reversal for redeployed employees and $17 million of cash payments; cumulative payments of about $46 million with roughly 70 employees (including Keysight employees) pending termination as of October 31, 2014, under the combined restructuring and manufacturing-streamlining actions. Expected to reduce annual cost of sales and operating expenses by roughly $50 million.
2014-10-31restructuringin_progress25020132015-01-31Not specifiedManufacturing operations — aimed at reducing annual cost of salesrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Streamlining of manufacturing operations, described as previously announced (specific quarter not stated), with an anticipated reduction of approximately 250 positions. Together with the targeted restructuring program, total headcount reductions of approximately 650 positions. Combined actions substantially complete in the U.S., with about 70 employees pending termination and ~$46 million paid as of October 31, 2014; international completion expected by end of fiscal Q1 2015.
2014-10-31divestiture_reductioncompleted8,3002013-09-192014-11-01GlobalElectronic Measurement business (Keysight Technologies, Inc.)Item_1_Business
f5-10k / GLM-5.3-flash-HTML
Spin-off of the entire electronic measurement business: 100% of Keysight common shares distributed to Agilent stockholders on November 1, 2014 (one day after fiscal year-end), one Keysight share for every two Agilent shares. Electronic measurement business employed approximately 8,300 at October 31, 2014; MD&A states Agilent headcount will be roughly 12,000 following the separation. Keysight results will be reported as discontinued operations beginning Q1 2015.
2014-10-31restructuringin_progress3002014-10-312015-10-31United Kingdom and United States (California)Life Sciences and Diagnostics — Nuclear Magnetic Resonance (NMR) product lineUSD 68 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Decision made in fourth quarter of fiscal 2014; charge comprises $16M workforce reduction, $19M asset impairments, $33M inventory and other special charges. About 300 jobs expected to be eliminated mostly within 12 months; restructuring accrual $17M at year-end, $2M paid in FY2014.
2014-10-31restructuringin_progress4002013-04-302015-01-31United States and internationalEnterprise-wide targeted restructuring programrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Program announced in second quarter of fiscal 2013 (original target 450 employees, reduced to 400 after about 50 redeployed). FY2014 activity only: $4M charge reversal and $17M cash payments; approximately 70 employees (including Keysight) pending termination at October 31, 2014. Announcement date approximate — filing states only the quarter.
2014-10-31restructuringin_progress2502015-01-31Not specifiedManufacturing operations streamliningrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Announcement date not disclosed. Combined with the targeted program, total headcount reductions are approximately 650 positions; international completion expected by end of first quarter of fiscal 2015.
2014-10-31divestiture_reductioncompleted8,3002013-09-192014-11-01WorldwideElectronic Measurement business (distributed as Keysight Technologies, Inc.)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Count is the electronic measurement business headcount at October 31, 2014, transferred with the spin-off completed November 1, 2014 (one Keysight share per two Agilent shares). Filing does not state a Keysight-specific headcount; post-separation Agilent headcount expected to be approximately 12,000. Pre-separation costs of $191M incurred in FY2014.
2014-10-31restructuringin_progress3002014-10-012015-10-31United Kingdom and CaliforniaLife Sciences and Diagnostics (NMR Business)USD 68 (millions)Item 1. Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
In the fourth quarter of 2014, Agilent announced it is exiting its NMR business. The company expects that this decision will eliminate about 300 jobs, mostly within the next 12 months. Charges of approximately $68 million were incurred.
2014-10-31restructuringin_progress4002013-04-012015-01-31GlobalAll SegmentsItem 7. MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
In the second quarter of 2013, Agilent accrued for a targeted restructuring program to reduce total headcount by approximately 450 regular employees. As a result of the Keysight separation, approximately 50 employees were redeployed, reducing the total headcount under this plan to 400 employees. Internationally, almost all activities expected to be completed by the end of the first quarter of fiscal 2015.
2014-10-31restructuringin_progress250GlobalManufacturingItem 7. MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
As part of streamlining manufacturing operations, Agilent anticipates the reduction of approximately 250 positions to reduce annual cost of sales.
2014-10-31restructuringin_progress3002014-10-312015-10-31United Kingdom, CaliforniaLife Sciences and Diagnostics (NMR Business)USD 68 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0
Exit of Nuclear Magnetic Resonance (NMR) business. Charges of approximately $68 million incurred for year ended Oct 31, 2014. Elimination of about 300 jobs, mostly within next 12 months.
2014-10-31restructuringin_progress4002013-04-012015-01-31GlobalCorporateMD&A
f5-10k / Qwen3.6-27B-Q8_0
Targeted restructuring program announced Q2 2013 to reduce headcount by approx 450 regular employees. Reduced to 400 employees after redeployment of 50. Expected to result in approx $50 million reduction in annual cost of sales and operating expenses.
2014-10-31restructuringin_progress250GlobalManufacturingMD&A
f5-10k / Qwen3.6-27B-Q8_0
Streamlining manufacturing operations. Anticipated reduction of approx 250 positions to reduce annual cost of sales.
2014-10-31restructuringin_progress300NMR [Member]USD 68,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
Expected positions to be eliminated
2014-10-31restructuringin_progressCost of Sales [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-10-31restructuringin_progressUSD 64,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-10-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-10-31restructuringin_progressResearch and Development Expense [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-10-31restructuringin_progressOther Restructuring [Member] / NMR [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-10-31restructuringin_progressEmployee Severance [Member] / NMR [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-10-31restructuringin_progressAsset impairment [Member] / NMR [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-10-31restructuringin_progress650Manufacturing Streamline and Targeted Restructuring Plans [Member]restructuring_footnote
f5-10k / no-ai-xblr
Expected positions to be eliminated
2014-10-31restructuringin_progress250Manufacturing Streamlining [Member]restructuring_footnote
f5-10k / no-ai-xblr
Expected positions to be eliminated
2014-07-31restructuringin_progress4002015-01-31Global (U.S. substantially complete; remaining actions international)Corporate-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Targeted workforce reduction originally covering about 450 employees (~2% of global workforce), announced in fiscal Q2 2013; roughly 50 employees were redeployed in connection with the Keysight separation, reducing the plan to 400. Approximately 140 employees were pending termination as of 2014-07-31. Restructuring accrual was $6M at 2014-07-31 (after a $4M reversal and $14M of cash payments YTD); expected annual cost savings of about $50M. International actions expected to complete by end of fiscal Q1 2015.
2014-07-31restructuringin_progress2502015-01-31GlobalManufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Manufacturing streamlining action previously announced by the filer; no announcement date stated. Combined with the targeted workforce reduction, total headcount reductions are approximately 650 positions. No separate charge disclosed for this component.
2014-07-31divestiture_reductionannounced2013-09-192014-11-30GlobalElectronic Measurement (Keysight Technologies)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Spin-off of the electronic measurement business as Keysight Technologies. Substantially all EM assets, liabilities and operations were transferred to Keysight effective 2014-08-01 (after period end); tax-free pro rata distribution expected early November 2014. Headcount transferring with the business is not quantified. Pre-separation costs of $123M were incurred in the nine months ended 2014-07-31, including costs of new employees recruited to operate the two separate companies.
2014-07-31restructuringin_progress6502013-04-302015-01-31GlobalGlobalrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Targeted restructuring and manufacturing streamlining reducing total headcount by approximately 650 positions. Approximately 140 employees pending termination as of July 31, 2014. Majority of international activities expected to complete by end of Q1 FY2015.
2014-07-31restructuringin_progressCost of Sales [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-07-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-07-31restructuringin_progress650USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2014-07-31restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-07-31restructuringin_progress250Manufacturing Streamlining [Member]restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2014-07-31restructuringin_progress400Targeted Restructuring Plan [Member]restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2014-04-30restructuringin_progress4002015-01-31GlobalCorporate-wide (targeted headcount reduction)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Program originally targeted ~450 employees (~2% of global workforce); ~50 redeployed due to Keysight separation, reducing plan to 400. Announced in second quarter of fiscal 2013 (exact date not disclosed). Restructuring accrual was $8M at 2014-04-30 after a $4M reversal in the six-month period; ~$41M paid cumulatively under both actions per MD&A. ~160 employees pending termination at quarter-end. Majority of international activity expected complete by end of fiscal Q1 2015.
2014-04-30restructuringin_progress2502015-01-31GlobalManufacturing (manufacturing streamlining)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Manufacturing streamlining to reduce annual cost of sales; announcement date not disclosed in this filing. U.S. activities substantially complete; international activities expected to complete by end of fiscal Q1 2015. Combined with targeted restructuring, total planned reductions are approximately 650 positions.
2014-04-30restructuringin_progress6502013-07-012015-01-31GlobalGlobalrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Total headcount reductions from targeted restructuring and manufacturing streamlining. Approximately 160 employees pending termination as of April 30, 2014. Majority of international activities expected to complete by end of Q1 FY2015.
2014-04-30restructuringin_progressEmployee Severance [Member]USD -4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-04-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-04-30restructuringin_progressCost of Sales [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-04-30restructuringin_progress650USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2014-04-30restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-04-30restructuringin_progress250Manufacturing Streamlining [Member]restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2014-04-30restructuringin_progress400Targeted Restructuring Plan [Member]restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2014-01-31restructuringin_progress4002%2014-10-31GlobalCompany-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Targeted program originally sized at ~450 employees (~2% of global workforce), accrued in fiscal Q2 2013; reduced to 400 after ~50 employees were redeployed following the Keysight separation announcement. Approximately 180 employees across all actions were pending termination at January 31, 2014. Restructuring accrual balance was $12M at quarter-end (from $24M at October 31, 2013), reflecting a $4M reversal and $8M of cash payments in the quarter; filer expects the majority of international actions complete by end of fiscal 2014 second half and an approximately $50M annual cost reduction when complete.
2014-01-31restructuringin_progress2502014-10-31GlobalManufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Manufacturing streamlining actions described as previously announced; no separate announcement date or charge disclosed. Filer states U.S. activities substantially complete and international activities largely complete by end of fiscal 2014 second half. Combined with the targeted program, total reductions are approximately 650 positions.
2014-01-31divestiture_reductionannounced2013-09-192014-11-30GlobalElectronic MeasurementMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Planned tax-free spin-off of the electronic measurement business into Keysight Technologies, expected to complete early November 2014; no headcount associated with the separation is quantified in the filing. Filer expects $140M of pre-separation expenses in fiscal 2014.
2014-01-31restructuringin_progress6502013-04-012014-07-31GlobalAll segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Targeted restructuring and manufacturing streamlining totaling approximately 650 positions. 50 employees redeployed, reducing headcount under plan to 400. 180 employees pending termination as of Jan 31, 2014. Majority of international activities expected to complete by end of second half of fiscal 2014.
2014-01-31restructuringin_progressEmployee Severance [Member]USD -4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-01-31restructuringin_progress650USD -4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2014-01-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-01-31restructuringin_progressCost of Sales [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-01-31restructuringin_progressResearch and Development Expense [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-01-31restructuringin_progress250Manufacturing Streamlining [Member]restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2014-01-31restructuringin_progress400Targeted Restructuring Plan [Member]restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2013-10-31restructuringin_progress4502%2013-022014-10-31USD 53 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Targeted program accrued in fiscal Q2 2013 in response to slow revenue growth, expected to cut total headcount by about 450 regular employees (~2 percent of global workforce). Approximately 250 employees were terminated and $29 million paid as of October 31, 2013. The $53 million FY2013 workforce-reduction accrual covers both this program and the manufacturing-streamlining action (combined ~700 positions) and is not separately allocated between them. U.S. activities substantially complete at fiscal year-end; international activities expected largely complete by end of fiscal H2 2014.
2013-10-31restructuringin_progress2502014-10-31Manufacturingrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Streamlining of manufacturing operations, previously announced (specific announcement date not disclosed), anticipated to reduce approximately 250 positions to lower annual cost of sales; 100 employees terminated as of October 31, 2013. Combined with the targeted restructuring program, total expected headcount reduction is approximately 700 positions; the combined FY2013 workforce-reduction accrual was $53 million (recorded under the targeted-program record). Expected completion of the majority of international activities by end of fiscal H2 2014.
2013-10-31divestiture_reductionannounced2013-09-192014-11Electronic MeasurementItem_1_Business
f5-10k / GLM-5.3-flash-HTML
Planned tax-free pro rata spin-off of the electronic measurement business into a separate public company, announced September 19, 2013 and expected early in November 2014. No affected-employee count is disclosed; the EM business employed approximately 8,300 people at fiscal year-end 2013 and would transfer out of the Agilent reporting entity. Company expects $100 million of pre-separation expenses in fiscal 2014 (transaction-related, not a workforce severance charge).
2013-10-31restructuringin_progress4502%2013-01-312014-10-31Worldwide (U.S. substantially complete; international wind-down through fiscal 2014)Company-wide (approximately 2% of global workforce)USD 53 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Targeted program accrued in Q2 FY2013 (quarter ended 2013-01-31; exact announcement date not disclosed) to reduce headcount by approximately 450 regular employees; expected to reduce annual cost of sales and operating expenses by approximately $50 million. Approximately 250 employees terminated and $29 million paid as of 2013-10-31. The $53 million charge is the total FY2013 restructuring accrual covering both this program and the manufacturing streamlining action below.
2013-10-31restructuringin_progress2502014-10-31WorldwideManufacturing operations streamliningrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Previously announced manufacturing streamlining anticipated to reduce approximately 250 positions to lower annual cost of sales; 100 employees terminated as of 2013-10-31. Announcement date not disclosed in this filing. Combined with the targeted program, total headcount reductions are approximately 700 positions.
2013-10-31restructuringin_progress4502%2013-04-012014-10-31GlobalAll segmentsUSD 53 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Targeted restructuring program expected to reduce headcount by approx 450 regular employees (2% of global workforce). Accrued $53 million in FY2013. Internationally, majority expected to complete by end of second half of fiscal 2014.
2013-10-31restructuringin_progress2502013-04-01GlobalManufacturingMD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Streamlining of manufacturing operations anticipated to reduce approx 250 positions to reduce annual cost of sales. No specific charge disclosed separately from the $53M total restructuring accrual.
2013-10-31restructuringin_progress4502%2013-04-012014-10-31GlobalGlobalUSD 53 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
Targeted restructuring program announced in Q2 2013 to reduce headcount by approx 450 regular employees (2% of global workforce). Accrued $53 million. As of Oct 31, 2013, approx 250 employees terminated under this program.
2013-10-31restructuringin_progress2502013-04-012014-10-31GlobalManufacturingMD&A
f5-10k / Qwen3.6-27B-Q8_0
Streamlining of manufacturing operations to reduce approx 250 positions. As of Oct 31, 2013, 100 employees terminated under this streamlining.
2013-10-31restructuringin_progressEmployee Severance [Member]USD 53,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-10-31restructuringin_progress700USD 53,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
Expected positions to be eliminated
2013-10-31restructuringin_progress100Manufacturing Streamlining [Member]restructuring_footnote
f5-10k / no-ai-xblr
2013-10-31restructuringin_progress250Targeted Restructuring Plan [Member]restructuring_footnote
f5-10k / no-ai-xblr
2013-07-31restructuringin_progress4502%2013-04-302013-10-31GlobalAll segments (approximately 2% of global workforce)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Targeted restructuring accrued in Q2 FY2013 (only quarter of announcement disclosed); expected to reduce annual cost of sales and operating expenses by approximately $50 million. A combined $56 million restructuring accrual was recorded for the nine months ended July 31, 2013 covering this program and the manufacturing streamlining below; the charge is not split between the two programs. Approximately 200 employees terminated and $15 million paid as of July 31, 2013 (combined across both actions). Announcement date reflects Q2 FY2013 end; exact date not disclosed.
2013-07-31restructuringin_progress2502013-04-302013-10-31GlobalManufacturing operationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Manufacturing streamlining previously announced; positions to be reduced to lower annual cost of sales. Combined with the targeted restructuring, total headcount reductions of approximately 700 positions. Announcement date reflects Q2 FY2013 end; exact announcement date not disclosed.
2013-07-31restructuringin_progress4502%2013-04-012013-10-31GlobalAll segmentsUSD 56 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Targeted restructuring program announced in Q2 2013 to reduce headcount by approx. 450 regular employees (2% of global workforce). Accrued $56 million for nine months ended July 31, 2013. Approx. 200 employees terminated and paid as of July 31, 2013. Expected completion by end of fiscal 2013.
2013-07-31restructuringin_progress2502013-04-012013-10-31GlobalManufacturingrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Streamlining of manufacturing operations anticipated to reduce approx. 250 positions. Included in total headcount reduction of approx. 700 positions.
2013-07-31restructuringin_progressEmployee Severance [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-07-31restructuringin_progressResearch and Development Expense [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-07-31restructuringin_progress200USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-07-31restructuringin_progressCost of Sales [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-07-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-07-31restructuringin_progress250Manufacturing Streamlining [Member]restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2013-07-31restructuringin_progress450Targeted Restructuring Plan [Member]restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2013-04-30restructuringin_progress4502%2013-04-302013-10-31GlobalCompany-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Targeted restructuring program accrued in Q2 FY2013 in response to slow revenue growth; approximately 450 regular employees, about 2% of global workforce. Exact announcement date not disclosed; stated only as second quarter of fiscal 2013 (date shown is quarter end). Combined restructuring charge for this program and the manufacturing streamlining action was $55 million for the three and six months ended April 30, 2013; charge not split between components. Timing and scope of reductions vary by local legal requirements.
2013-04-30restructuringin_progress1702013-04-302013-10-31Manufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Previously announced manufacturing streamlining: reduction of approximately 170 positions to reduce annual cost of sales. Combined with the targeted restructuring, total headcount reductions of approximately 600 positions; majority expected complete by end of fiscal 2013. Combined charge of $55 million not split between components. Exact announcement date not disclosed; date shown is quarter end.
2013-04-30restructuringin_progress4502%2013-04-302013-10-31GlobalAll segmentsUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Targeted restructuring program to reduce headcount by approx. 450 regular employees (2% of global workforce). Expected to reduce annual expenses by approx. $50 million. Majority of actions expected to complete by end of fiscal year 2013.
2013-04-30restructuringin_progress1702013-04-302013-10-31GlobalManufacturingrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Streamlining manufacturing operations, reducing approx. 170 positions to reduce annual cost of sales. Included in total headcount reduction of approx. 600 positions.
2013-04-30restructuringin_progressEmployee Severance [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-04-30restructuringin_progressResearch and Development Expense [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-04-30restructuringin_progress600USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2013-04-30restructuringin_progressCost of Sales [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-04-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-04-30restructuringin_progress450Targeted Restructuring Plan [Member]restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2013-04-30restructuringin_progress170Manufacturing Streamlining [Member]restructuring_footnote
f5-10q / no-ai-xblr
Expected positions to be eliminated
2012-10-31acquisition_additioncompleted2012-05-162012-06-21DenmarkDiagnostics and GenomicsMD&A
f5-10k / GLM-5.3-flash-HTML
Dako A/S acquisition completed June 21, 2012 under a share purchase agreement dated May 16, 2012; total consideration approximately $2.143 billion ($1.4 billion to the seller and $743 million to satisfy Dako's outstanding debt), funded with existing cash. Dako was combined into the newly formed Diagnostics and Genomics segment. No Dako employee count was disclosed; MD&A attributes a significant proportion of the fiscal 2012 headcount increase to this acquisition.
2012-10-31restructuringin_progress20092014-10-31USD 4 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
FY 2009 Plan, announced in the first half of 2009. No restructuring or workforce reduction expense was recorded in fiscal 2012; current-year activity consisted solely of $4 million of cash payments on excess-facility lease obligations. Workforce reduction payments were largely complete in fiscal 2010. Remaining accrual of $11 million at October 31, 2012 relates to consolidation of excess facilities, with payments expected primarily complete by end of fiscal 2014. No fiscal 2012 headcount reduction is attributed to this program.
2012-10-31acquisition_additioncompleted2012-05-162012-06-21DenmarkDiagnostics and Genomicsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of 100% of Dako A/S for approximately $2,143 million; headcount added through the acquisition is not disclosed. Consolidated headcount rose from approximately 18,700 (FY2011) to approximately 20,500 (FY2012), with a significant portion of the increase attributed to Dako.
2012-10-31restructuringin_progress2014-10-31GlobalEnterpriseUSD 0 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY2009 Plan remained open with an $11 million accrual balance at fiscal year-end; no restructuring expense and no employees affected recorded in fiscal 2012. Remaining cash payments relate to lease obligations for consolidated facilities, expected to be substantially complete by end of fiscal 2014.
2012-10-31acquisition_additioncompleted2012-06-21GlobalDiagnostics and GenomicsItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Acquisition of Dako A/S completed June 21, 2012. Significant proportion of headcount increase in 2012 compared to 2011 attributed to this acquisition.
2012-10-31restructuringcompleted2009-01-012014-10-31GlobalCorporateUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY 2009 Plan workforce reduction payments largely complete in FY 2010. Lease payments primarily complete by end of FY 2014. No income statement expense recorded in FY 2012.
2012-10-31restructuringcompleted2009-04-012014-10-31GlobalAll SegmentsUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in fiscal 2010. Lease payments expected to be complete by end of fiscal 2014. No income statement expense recorded in 2012.
2012-10-31acquisition_additioncompleted2012-06-212012-06-21DenmarkDiagnostics and Genomicsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0
Acquisition of Dako A/S on June 21, 2012. Significant proportion of headcount increase in 2012 attributed to this acquisition.
2012-10-31restructuringin_progressInventory Charges [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-10-31restructuringin_progressEmployee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-10-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-10-31restructuringin_progressImpairment Of Long Lived Assets Held For Use And Purchased Intangible Assets [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-10-31restructuringin_progressFacility Closing [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-07-31acquisition_additioncompleted2012-05-162012-06-21DenmarkDiagnostics and Genomicsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Dako A/S acquired June 21, 2012 for approximately $2,144 million; no employee count disclosed. MD&A attributes most of the headcount increase to 20,200 from this acquisition
2012-07-31acquisition_additioncompleted2012-06-21DenmarkDiagnostics and GenomicsMD&A
f5-10q / Qwen3.6-27B-Q8_0
Acquisition of Dako A/S completed on June 21, 2012. Headcount increase attributed to this acquisition, though specific employee count not disclosed.
2012-07-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-04-30acquisition_additionannounced2012-05-16DenmarkLife Sciences (diagnostics/pathology)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter agreement to acquire 100% of Dako A/S for cash enterprise value of approximately $2.2 billion; no employee count disclosed. FTC granted early termination of HSR waiting period on 2012-05-30; other closing conditions pending.
2012-01-31acquisition_additioncompletedLife SciencesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Halo Genomics acquisition cited as expanding the SureSelect portfolio; no headcount added disclosed
2012-01-31acquisition_additioncompletedLife SciencesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
BioSystem Development acquisition cited for microchromatography sample-prep capability; no headcount added disclosed
2011-10-31reduction_in_forcecompleted2009USD 1 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Workforce-reduction component of the multi-year FY 2009 restructuring plan announced in the first half of 2009. Fiscal 2011 activity was a $1M charge and $9M of cash payments, with the related liability fully settled by October 31, 2011; severance payments were largely complete in fiscal 2010. Employee counts not disclosed; the charge shown is the current-year portion of the program, not cumulative.
2011-10-31restructuringin_progress20092014-10-31USD 1 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Consolidation-of-excess-facilities component of the FY 2009 plan; fiscal 2011 included a $1M charge and $12M of lease-related payments, leaving a $15M accrual at October 31, 2011. Lease payments expected to be primarily complete by the end of fiscal 2014.
2011-10-31restructuringin_progress2014-10-31GlobalEnterprise-wideUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY2009 Plan announced first half of fiscal 2009; FY2011 expense of $2M (workforce reduction $1M, excess facilities $1M). Workforce reduction payments largely complete in fiscal 2010; lease payments expected complete by end of fiscal 2014. Employees affected in FY2011 not disclosed.
2011-10-31acquisition_additioncompletedNot disclosedLife Sciences; Chemical AnalysisUSD 96 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Three businesses acquired during fiscal 2011 (A2 Technologies, Lab901, Biocius Life Sciences) for total cost of $96 million net of cash acquired; headcount added not disclosed. Charge value represents acquisition cost, not a severance or restructuring charge.
2011-10-31restructuringin_progress2009-01-012014-10-31GlobalAll segmentsUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in FY 2010. Lease payments expected to be complete by end of FY 2014. Total restructuring, asset impairments and other special charges recorded in FY 2011 were $2 million.
2011-10-31acquisition_additioncompleted2010-05-14GlobalLife Sciences and Chemical AnalysisItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Acquisition of Varian, Inc. completed May 14, 2010. Varian employees integrated into Life Sciences and Chemical Analysis segments. Headcount impact included in segment totals.
2011-10-31divestiture_reductioncompleted2010-05-01GlobalElectronic MeasurementItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Sale of Network Solutions Division (NSD) to JDS Uniphase Corporation completed May 1, 2010. NSD employees transferred to JDSU.
2011-10-31divestiture_reductioncompleted2010-02-02GlobalLife SciencesItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Sale of Hycor Biomedical Inc. to Linden LLC completed February 2, 2010. Hycor employees transferred to Linden LLC.
2011-10-31restructuringin_progress2009-04-012014-10-31GlobalAll segmentsUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in FY 2010. Lease payments expected to be complete by end of FY 2014. $2 million in restructuring charges recorded in FY 2011.
2011-10-31acquisition_additioncompleted2010-05-142010-05-14GlobalLife Sciences and Chemical Analysisbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0
Acquired Varian, Inc. on May 14, 2010. Headcount added not explicitly quantified in employee count, but included in total workforce.
2011-10-31acquisition_additioncompleted2011-10-312011-10-31GlobalLife SciencesMD&A
f5-10k / Qwen3.6-27B-Q8_0
Acquired A2 Technologies, Lab901 and Biocius Life Sciences Inc. during fiscal year 2011. Headcount added not explicitly quantified.
2011-10-31divestiture_reductioncompleted2010-05-012010-05-01GlobalElectronic Measurementdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0
Sold Network Solutions Division (NSD) to JDS Uniphase Corporation on May 1, 2010. Headcount removed not explicitly quantified.
2011-10-31divestiture_reductioncompleted2010-02-022010-02-02GlobalLife Sciencesdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0
Sold Hycor Biomedical Inc. to Linden LLC on February 2, 2010. Headcount removed not explicitly quantified.
2011-07-31restructuringin_progress2009-01-012014-10-31GlobalCorporate and DivisionalUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in FY 2010. Lease payments expected to be complete by end of fiscal 2014. $2 million expense recorded for nine months ended July 31, 2011.
2011-07-31restructuringin_progress2005-10-012012-07-31GlobalCorporate and Divisionalrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2005 restructuring program largely complete. Remaining obligations relate primarily to lease obligations expected to be satisfied over approximately the next year.
2011-04-30acquisition_additioncompletedLife Sciences; Chemical AnalysisMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
A2 Technologies, Lab901 and Biocius Life Sciences acquired during the six months ended April 30, 2011 for $96 million total consideration net of cash acquired; no employee counts disclosed
2011-04-30restructuringin_progress2009-01-012014-10-31GlobalCorporate and DivisionalUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in FY 2010. Remaining obligations relate primarily to lease obligations expected to be satisfied by end of fiscal 2014. Total restructuring accrual balance was $23 million as of April 30, 2011.
2011-04-30acquisition_additioncompleted2010-05-14GlobalLife Sciences and Chemical AnalysisMD&A
f5-10q / Qwen3.6-27B-Q8_0
Acquisition of Varian, Inc. completed May 14, 2010. Headcount increased from approx. 16,100 to 18,500 mainly due to this acquisition.
2011-04-30acquisition_additioncompleted2011-04-30GlobalVariousUSD 96 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0
Acquired A2 Technologies, Lab901, and Biocius Life Sciences Inc. in the three and six months ended April 30, 2011 for $96 million total consideration.
2011-01-31acquisition_additioncompleted2009-07-262010-05-14GlobalLife Sciences; Chemical Analysisbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Merger completed May 14, 2010; consideration approximately $1,507 million plus option/award settlements. No employee count disclosed. MD&A attributes most of the year-over-year headcount increase (16,350 to 18,385) to this acquisition.
2011-01-31restructuringin_progress2009-01-012014-10-31Outside the United StatesElectronic MeasurementUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY2009 Plan: a small number of non-U.S. Electronic Measurement employees still pending termination at quarter end; no count disclosed. Total restructuring accrual balance $28 million at 2011-01-31; $2 million expense recognized in the quarter. Workforce reduction payments largely complete in FY2010; lease payments expected complete by end of FY2014. Announcement date approximate (program announced in first half of 2009).
2011-01-31divestiture_reductioncompletedGlobalElectronic Measurement (network solutions); Life Sciences (Hycor)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
MD&A references recently divested network solutions and Hycor businesses as reducing reported orders/revenue growth; no headcount removed disclosed and no divestiture footnote in this filing.
2011-01-31restructuringin_progress2009-04-012014-10-31Outside of the U.S.Electronic MeasurementUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY 2009 Plan. Small number of employees pending termination. Lease payments expected complete by end of fiscal 2014.
2010-10-31restructuringin_progress20092014-10-31WorldwideGlobal infrastructure organization and electronic measurement segmentUSD 64 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Multi-year FY 2009 Plan announced in the first half of fiscal 2009; figures captured are current-year (FY2010) activity. FY2010 income statement expense of $64M comprised $39M workforce reduction, $19M consolidation of excess facilities and $6M asset impairment. FY2010 cash payments were $92M. Workforce reduction payments, primarily severance, largely complete in FY2010; supplier inventory payments expected complete in FY2011; lease payments primarily complete by end of fiscal 2014. A small number of electronic measurement employees remained pending termination at October 31, 2010; remaining accrual of $35M ($8M workforce reduction, $26M excess facilities, $1M inventory special charges). Employee counts affected were not disclosed in this filing.
2010-10-31acquisition_additioncompleted2009-07-262010-05-14Life Sciences and Chemical Analysis (Varian, Inc.)USD 102 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML
Acquisition of Varian, Inc. completed May 14, 2010 for total cash purchase price of approximately $1.5 billion ($52 per share). Specific headcount added was not disclosed; MD&A attributes the fiscal 2010 headcount increase (from approximately 16,800 to approximately 18,500) to this acquisition. Goodwill from the acquisition was allocated primarily to Life Sciences ($184M) and Chemical Analysis ($603M). Associated value shown is fiscal 2010 acquisition and integration costs directly related to the merger, substantially recorded in selling, general and administrative expenses.
2010-10-31divestiture_reductioncompleted2010-02-022010-02-02Life Sciences — Hycor Biomedical Inc.other
f5-10k / GLM-5.3-flash-HTML
Hycor Biomedical Inc., an in-vitro diagnostics maker within the life sciences business, sold to Linden LLC, a Chicago-based healthcare private equity firm, on February 2, 2010. Number of employees removed not disclosed. Hycor-specific proceeds not individually disclosed; total fiscal 2010 divestiture proceeds of $205M related primarily to the network solutions and Hycor businesses. Related intangible impairments of $13M and goodwill reduction of $1M were recorded in connection with the divestiture.
2010-10-31divestiture_reductioncompleted2010-05-012010-05-01Electronic Measurement — Network Solutions Division (NSD)USD 132 (millions)other
f5-10k / GLM-5.3-flash-HTML
Network Solutions Division (network assurance, network protocol test and drive test products) sold to JDS Uniphase Corporation on May 1, 2010. Number of employees removed not disclosed. Associated value is a net gain on sale of $132 million (a gain, not a charge); JDSU paid $160 million. Results of NSD operations were not significant to fiscal 2010 income from operations. Goodwill reduction of $13M related to this divestiture.
2010-10-31restructuringin_progress2009-06-302014-10-31GlobalGlobal infrastructure organization and electronic measurementUSD 39 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY2009 Plan announced in first half of FY2009; FY2010 workforce-reduction expense of $39M recorded, with a small number of electronic measurement employees still pending termination at year-end; lease payments expected to run through fiscal 2014. Announcement date is approximate (first half of fiscal 2009).
2010-10-31acquisition_additioncompleted2009-07-262010-05-14GlobalLife Sciences and Chemical Analysisbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Varian acquisition closed 2010-05-14 for ~$1.5B; MD&A attributes the increase in headcount from 16,800 to 18,500 to this acquisition, but no employee count is disclosed for Varian.
2010-10-31divestiture_reductioncompleted2010-05-012010-05-01GlobalElectronic Measurement — Network Solutions Divisiondiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
NSD sold to JDS Uniphase for $160M with a $132M net gain; no employee count disclosed.
2010-10-31divestiture_reductioncompleted2010-02-022010-02-02GlobalLife Sciences — Hycor Biomedical Inc.discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Hycor sold to Linden LLC; no employee count disclosed.
2010-10-31divestiture_reductioncompleted2010-05-192010-05-19GlobalChemical Analysis — Varian laboratory GC, triple quad GC-MS, ICP-MS and Agilent micro GC businessesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Divestitures required as conditions of European Commission merger approval and FTC consent order, sold for ~$33M; no employee count disclosed.
2010-10-31restructuringin_progress2009-04-012014-10-31GlobalGlobal Infrastructure Organization and Electronic MeasurementUSD 64 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in fiscal 2010. Lease payments primarily complete by end of fiscal 2014. Small number of employees within electronic measurement pending termination as of October 31, 2010. Total restructuring, asset impairments and other special charges were $64 million in 2010.
2010-10-31acquisition_additioncompleted2010-05-142010-05-14GlobalLife Sciences and Chemical AnalysisItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Acquisition of Varian, Inc. completed May 14, 2010. Headcount increase in 2010 compared to 2009 was due to the Varian acquisition.
2010-10-31divestiture_reductioncompleted2010-05-012010-05-01GlobalElectronic MeasurementItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Sale of Network Solutions Division (NSD) completed May 1, 2010.
2010-10-31divestiture_reductioncompleted2010-02-022010-02-02GlobalLife SciencesItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Sale of Hycor Biomedical Inc. completed February 2, 2010.
2010-10-31restructuringin_progress2009-04-012014-10-31GlobalAll segmentsUSD 64 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in FY 2010. Lease payments primarily complete by end of FY 2014. Small number of employees in electronic measurement pending termination as of Oct 31, 2010. Total restructuring charges in FY 2010 were $64 million.
2010-10-31acquisition_additioncompleted2010-05-142010-05-14GlobalLife Sciences and Chemical AnalysisItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0
Acquisition of Varian, Inc. completed May 14, 2010. Headcount increase attributed to this acquisition in MD&A.
2010-10-31divestiture_reductioncompleted2010-05-012010-05-01GlobalElectronic MeasurementItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0
Sale of Network Solutions Division (NSD) to JDS Uniphase Corporation completed May 1, 2010.
2010-10-31divestiture_reductioncompleted2010-02-022010-02-02GlobalLife SciencesItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0
Sale of Hycor Biomedical Inc. to Linden LLC completed February 2, 2010.
2010-10-31restructuringin_progressUSD 39,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2010-07-31acquisition_additioncompleted3,2002010-05-142010-05-14GlobalLife Sciences; Chemical AnalysisMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Approximate headcount added via the Varian, Inc. merger completed May 14, 2010; figure is stated as approximate in the MD&A headcount discussion. Business combination footnote (Note 3) does not disclose an employee count.
2010-07-31restructuringin_progress20092010-10-31GlobalElectronic MeasurementUSD 56 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY 2009 Plan announced in the first half of 2009. Fewer than 100 employees in electronic measurement remained pending termination as of July 31, 2010; exact count not disclosed. Associated charge is total restructuring, asset impairment and other special charges recorded across all plans for the nine months ended July 31, 2010 (quarterly figure was $6 million). Restructuring accrual balance was $37 million at July 31, 2010. Workforce reduction payments expected largely complete by fiscal year-end 2010.
2010-07-31divestiture_reductioncompleted2010-05-012010-05-01GlobalElectronic Measurement — Network Solutions DivisionMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Headcount removed through the divestiture not disclosed; filing states NSD results were not significant to income from operations.
2010-07-31divestiture_reductioncompleted2010-05-192010-05-19GlobalChemical Analysis — Varian laboratory GC, triple quadrupole GC-MS, ICP-MS businesses and Agilent micro GCbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Regulatory-mandated divestiture (European Commission merger approval and FTC consent order) completed May 19, 2010 for approximately $42 million; associated headcount not disclosed.
2010-07-31restructuringin_progress2009-01-012010-10-31GlobalElectronic MeasurementUSD 56 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in first half of 2009. Less than 100 employees within electronic measurement pending termination as of July 31, 2010. Workforce reduction payments expected largely complete by end of fiscal 2010.
2010-07-31acquisition_additioncompleted3,2002010-05-142010-05-14GlobalLife Sciences, Chemical AnalysisMD&A
f5-10q / Qwen3.6-27B-Q8_0
Acquisition of Varian, Inc. completed May 14, 2010. Headcount increase includes approximately 3,200 Varian employees.
2010-04-30restructuringin_progress1502010-10-31Electronic Measurementrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY 2009 Plan announced in the first half of 2009 (exact date not disclosed); count reflects employees still pending termination at April 30, 2010. Workforce reduction payments expected largely complete by fiscal year-end 2010; lease payments over approximately four years. Restructuring accrual balance was $50 million at April 30, 2010 (all plans combined, not program-specific).
2010-04-30acquisition_additionannounced2010-05-142010-05-14Life Sciences / Chemical Analysissubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter acquisition completed May 14, 2010 for approximately $1.5 billion; acquired headcount not disclosed in this filing. Initial purchase price accounting incomplete.
2010-04-30divestiture_reductionannounced2010-05-012010-05-01Electronic Measurement — Network Solutions Divisionsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter divestiture completed May 1, 2010 for $165 million; associated headcount not disclosed.
2010-04-30divestiture_reductionannounced2010-05-192010-05-19Chemical Analysis — divested GC, GC-MS, ICP-MS and micro GC businessessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter sale completed May 19, 2010 for approximately $40 million; associated headcount not disclosed. A related divestiture during the quarter reduced other intangibles by $13 million, with headcount impact not disclosed.
2010-04-30restructuringin_progress2009-01-012010-10-31GlobalElectronic MeasurementUSD 50 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in first half of 2009. Approximately 150 employees within electronic measurement pending termination as of April 30, 2010. Workforce reduction payments expected largely complete by end of fiscal 2010. Total restructuring and other special accruals were $50 million.
2010-01-31restructuringin_progress3,8002008-122010-06-30GlobalGlobal infrastructure organization and electronic measurement segmentUSD 315 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY 2009 Plan consolidates actions announced December 2008, February 2009 and March 2009; approximately 3,800 regular positions to be eliminated, with expected annual savings of about $525 million. Approximately 300 electronic measurement employees remained subject to termination at January 31, 2010; $34 million of charges incurred in the quarter. Program disclosed only as a consolidated total.
2010-01-31divestiture_reductionannounced2010-02-11Electronic Measurement — Network Solutions Divisionsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Definitive agreement to sell the Network Solutions Division to JDS Uniphase for $165 million cash, subject to closing conditions and regulatory approval; associated headcount not disclosed.
2010-01-31restructuringin_progress3,8002009-03-012010-06-30GlobalGlobal workforceUSD 34 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in Q1-Q2 2009. Total headcount reductions approx 3,800. $34M charges incurred in Q1 2010. Completion expected by Q2 2010.
2010-01-31divestiture_reductionannounced2010-02-11Electronic Measurementsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0
Agreement to sell Network Solutions Division to JDSU for $165M. Employee count not disclosed.
2009-10-31restructuringin_progress3,8002008-122010-04-30GlobalGlobal Infrastructure Organization; Electronic Measurement; Semiconductor and Board TestUSD 315 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
FY 2009 Plan announced December 2008 with about 500 initial position reductions, then expanded in February and March 2009 by roughly 3,300 additional positions across the global infrastructure organization and the electronic measurement and semiconductor and board test segments, including exit of the inspection businesses. Aggregate expected pre-tax charges about $315 million; $267 million incurred in fiscal 2009 ($202 million workforce reduction, $18 million facilities consolidation, $27 million asset impairments, $20 million inventory-related charges). Majority of activities completed by October 31, 2009 with remainder expected by end of fiscal Q2 2010; about 600 electronic measurement employees were pending termination at year-end. Expected annual operating savings about $525 million. Position counts are approximate regular-employee reductions for the full plan; percent of workforce not disclosed.
2009-10-31restructuringin_progress3,8002008-12-012010-04-30GlobalGlobal infrastructure organization; electronic measurement; semiconductor and board testUSD 315 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY 2009 Plan: announced Dec 2008, expanded Feb 2009 and Mar 2009. Approximately $315M expected pre-tax charges in aggregate; $267M incurred in FY2009 (incl. $27M asset impairments, $20M inventory special charges). Workforce reductions of ~3,800 regular positions; majority of actions complete by 2009-10-31 with remainder expected by end of Q2 FY2010. Approximately 600 electronic measurement employees pending termination at year-end.
2009-10-31othercompleted2009-01-012009-10-31GlobalCompany-wideMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Company-wide wage reductions implemented January 2009, generating approximately $70M of cash savings in FY2009; fully restored to all employees effective 2009-11-01. No headcount reduction associated.
2009-10-31restructuringin_progress3,8002008-12-012010-04-30GlobalGlobal Infrastructure, Electronic Measurement, Semiconductor and Board TestUSD 315 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY 2009 Plan announced Dec 2008, expanded Feb/Mar 2009. Expected to result in workforce reductions of approx 3,800 regular positions and annual operating savings of approx $525 million. Total pre-tax charges approx $315 million. Majority completed by Oct 31, 2009; remainder expected by end of Q2 FY2010. Approx 600 employees in electronic measurement pending termination as of Oct 31, 2009.
2009-10-31restructuringin_progress3,8002008-12-012010-06-30WorldwideAll SegmentsUSD 315 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in Dec 2008, expanded Feb/Mar 2009. Expected to result in workforce reductions of approximately 3,800 regular positions and pre-tax charges of approx $315 million. Majority completed by Oct 31, 2009; remainder expected by end of Q2 FY2010.
2009-07-31restructuringin_progress3,8002008-12-012010-04-30GlobalGlobal infrastructure organization; electronic measurement; semiconductor and board testUSD 315 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY 2009 Plan announced December 2008 and expanded February and March 2009 (announcement date shown is the initial announcement). Approximately 2,000 of the 3,800 positions had left Agilent as of 2009-07-31; majority of actions expected complete by 2009-10-31, remainder by end of fiscal Q2 2010. $210M of the ~$315M expected pre-tax charges incurred in the nine months ended 2009-07-31; expected annual operating savings ~$525M. Includes $24M asset impairments and $22M inventory special charges.
2009-07-31acquisition_additionannounced2009-07-262009-12-31GlobalBio-analytical measurement (life science and applied markets)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Merger agreement dated 2009-07-26; estimated $1.5B total purchase price at $52.00 cash per Varian share plus cashed-out options and assumed debt. No headcount added disclosed; closing subject to Varian shareholder approval and U.S./EU antitrust clearance, expected before calendar year-end 2009.
2009-07-31restructuringin_progress3,8002009-02-012010-04-30GlobalGlobal Infrastructure Organization, Electronic Measurement, Semiconductor and Board TestUSD 315 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in Q1 2009 and expanded in Q2 2009. Total headcount reductions of approximately 3,800 positions. Approximately 2,000 employees had left as of July 31, 2009. Majority of actions expected complete by Oct 31, 2009, remainder by Q2 FY2010. Aggregate pre-tax charges expected ~$315 million.
2009-04-30restructuringin_progress3,8002008-122010-04-30GlobalGlobal infrastructure organization; electronic measurement; semiconductor and board testUSD 315 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY 2009 Plan announced Dec 2008, expanded Feb 2009 and Mar 2009; ~3,800 regular positions to be eliminated, expected annual savings ~$525M. ~650 employees had left as of 2009-04-30; $134M of charges incurred in six months ended 2009-04-30. Majority of activities expected complete by 2009-10-31, remainder by end of Q2 FY2010.
2009-04-30plant_closureannounced2009-02GlobalSemiconductor and board test — inspection businessesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Feb 2009 announcement to exit the inspection businesses in the semiconductor and board test segment; $23M of special charges for excess inventory and $17M of asset impairments recorded in six months ended 2009-04-30. Headcount impact not separately disclosed; part of the consolidated FY 2009 Plan.
2009-04-30restructuringin_progress3,8002008-12-012010-04-30GlobalGlobal workforce, Electronic Measurement, Semiconductor and Board Test, Global Infrastructure OrganizationUSD 315 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY 2009 Plan announced Dec 2008, expanded Feb/Mar 2009. Total headcount reductions approx 3,800. Approx 650 employees left as of Apr 30, 2009. Majority of activities expected to complete by Oct 31, 2009, remainder by end of Q2 FY2010. Expected aggregate pre-tax charges approx $315 million.
2009-01-31restructuringin_progress5002008-122009-10-31GlobalGlobal workforce of regular employeesUSD 48 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY 2009 Plan announced December 2008; also eliminates 300 temporary positions. $48M charged in Q1 FY2009 (incl. $13M asset impairments, $22M excess inventory special charges), with ~$107M expected for the remainder of FY2009; ~250 of the positions notified as of 2009-01-31. Expected annual savings ~$65M from this initial program. Combined with the February 2009 expansion, aggregate pre-tax charges expected ~$155M and annual savings ~$215M across ~1,100 positions.
2009-01-31restructuringannounced6002009-02-172009-10-31GlobalSemiconductor & Board Test (inspection businesses: automated optical inspection, automated X-ray inspection) and Global Infrastructure Organizationsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter expansion of the FY 2009 Plan announced 2009-02-17, bringing total planned reductions to ~1,100 regular positions. Exited inspection businesses had combined revenue of ~$55M for FY2008. Combined program expected to record ~$155M aggregate pre-tax charges, mostly cash; expected annual savings ~$150M from these additional actions.
2009-01-31restructuringin_progress5002008-12-012009-10-31GlobalGlobal workforce of regular employeesUSD 48 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY 2009 Plan announced in Q1 2009 (Dec 2008) to reduce ~500 regular positions. $48M total charges recorded in Q1 2009 ($13M workforce reduction, $22M inventory/special charges, $13M asset impairments). About 250 employees notified as of Jan 31, 2009.
2009-01-31restructuringannounced6002009-02-172009-10-31GlobalSemiconductor and board test segment; Global infrastructure organizationUSD 155 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0
Additional actions announced Feb 17, 2009 to exit inspection businesses and restructure global infrastructure. Reduces ~600 regular positions. Combined with prior plan, total headcount reduction is ~1,100. Aggregate pre-tax charges expected ~$155M.
2008-10-31acquisition_additioncompleted2007-12-18United States (California)Bio-analytical measurement (lab automation / robotics)USD 111 (millions)other
f5-10k / GLM-5.3-flash-HTML
Acquisition of Velocity11, a designer, manufacturer and marketer of robotic solutions, completed December 18, 2007 (first quarter of fiscal 2008) for approximately $111 million in cash for 100 percent of outstanding shares and vested employee options. Number of employees added through the acquisition is not disclosed. The $111 million is purchase consideration (charge label 'other'), not a severance or restructuring charge.
2008-10-31restructuringin_progress2005USD -4 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
FY2005 Plan (announced in the fourth quarter of fiscal 2005) is largely complete. Fiscal 2008 activity: net restructuring/asset impairment charge of $(4) million (a first-quarter credit from reducing the estimated excess-facilities liability), $18 million of cash payments, and a $10 million accrual remaining at October 31, 2008, entirely related to consolidation of excess facilities. The workforce-reduction component required no fiscal 2008 charges and was fully settled ($1 million cash payment, balance zero). Employee counts were disclosed only in prior fiscal years. Remaining obligations are primarily lease obligations expected to be satisfied over approximately the next three years. Charge value shown as fiscal-2008 net credit.
2008-10-31restructuringannounced5002008-12-122009-10-31GlobalUSD 55 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML
Regular-positions component of a targeted restructuring approved December 12, 2008 in response to deteriorating economic conditions; the program comprises approximately 500 regular and 300 temporary positions (see companion record). Majority of activities expected complete by May 31, 2009, remainder by October 31, 2009. The approximately $55 million pre-tax charge (mostly employee severance; substantially all cash) relates to the entire program and is recorded on this record only to avoid double counting.
2008-10-31restructuringannounced3002008-12-122009-10-31Globalsubsequent_events
f5-10k / GLM-5.3-flash-HTML
Temporary-positions component of the same December 12, 2008 targeted restructuring program disclosed as a subsequent event; the approximately $55 million total program charge is captured on the companion regular-positions record.
2008-10-31restructuringin_progress2005-10-31GlobalCompany-widerestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY2005 Plan announced in Q4 2005 and described as largely complete; no headcount reduction attributed to FY2008. FY2008 activity was a $4M reduction to the excess-facilities accrual and $18M of cash payments, leaving a $10M balance at year-end, with remaining obligations relating to lease obligations over roughly three years.
2008-10-31restructuringannounced8002008-12-122009-10-31GlobalBusinesses most severely impacted by the economic downturnUSD 55 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Targeted restructuring approved after fiscal year-end; comprises approximately 500 regular and 300 temporary positions, mostly severance. Majority of activities expected complete by 2009-05-31 with the remainder by 2009-10-31.
2008-10-31acquisition_additioncompleted2007-12-182007-12-18Bio-Analytical Measurement (laboratory automation and robotics)USD 111 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Velocity11 acquisition closed in Q1 FY2008 for approximately $111 million cash; acquired headcount not disclosed. Seven acquisitions plus a minority-interest buyout occurred in FY2008 ($103M of intangibles, $67M of goodwill); no aggregate acquired headcount disclosed.
2008-10-31restructuringannounced8002008-12-122009-10-31GlobalAgilent businesses most severely impacted by economic downturnUSD 55 (millions)subsequent_events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Announced December 12, 2008. Global workforce reduced by approximately 500 regular and 300 temporary positions. Majority of activities expected to be completed by May 31, 2009, remainder by October 31, 2009. Pre-tax restructuring charges of approximately $55 million, mostly related to employee severance.
2008-10-31restructuringin_progress2008-12-122009-10-31GlobalUSD 55 (millions)subsequent_events
f5-10k / Qwen3.6-27B-Q8_0
Announced Dec 12, 2008. Expected reduction of approx 500 regular and 300 temporary positions. Majority of activities expected by May 31, 2009.
2008-07-31restructuringcompletedrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY2005 Plan announced in Q4 2005 is complete; no employee counts disclosed. Remaining $12M accrual (down from $32M at Oct 31, 2007) relates primarily to lease obligations over roughly four years. No restructuring charges in Q3 FY2008; nine-month activity included a $4M benefit from reduced excess-facility estimates and $16M of cash payments.
2008-07-31restructuringin_progressConsolidation of Excess FacilitiesUSD -4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Reduction in estimated liability for consolidation of excess facilities due to changes in underlying property markets. No employee count disclosed.
2008-04-30restructuringin_progress2005-10-01restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY2005 Plan announced in Q4 2005 is largely complete; no employee-affected count disclosed. Six months ended April 30, 2008 shows no workforce-reduction income statement expense (accrual reduced from $1M to $0 via cash payments); remaining obligations are primarily lease obligations expected to be satisfied over approximately the next four years. Restructuring accrual total was $20M at April 30, 2008 (down from $32M at October 31, 2007), including a $4M reduction in the excess-facilities estimate due to property market changes.
2008-04-30acquisition_additioncompleted2007-12-182007-12-18Bio-analytical Measurementbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Velocity11 (robotic solutions designer/manufacturer) completed December 18, 2007 for approximately $111 million cash; headcount added not disclosed. MD&A attributes the year-over-year headcount increase (approximately 18,900 to approximately 19,500) entirely to acquisitions.
2008-04-30restructuringin_progressUSD -4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Reduction in estimated liability for consolidation of excess facilities due to changes in underlying property markets. No employee count disclosed.
2008-01-31restructuringin_progress2005-10-01USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY2005 Plan announced in Q4 2005 is largely complete; remaining obligations are primarily lease obligations expected to be satisfied over about four years. $1 million accrued at January 31, 2008 for amounts payable to employees impacted by the plan, expected to be paid within two quarters. No employees-affected count disclosed for the current quarter.
2008-01-31acquisition_additioncompleted2007-12-182007-12-18Bio-analytical Measurementbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Velocity11 (robotic solutions designer/manufacturer) completed December 18, 2007 for approximately $111 million cash; results included from date of acquisition. Headcount added through the acquisition is not disclosed.
2008-01-31restructuringin_progressUSD -4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Reduction in estimated liability for consolidation of excess facilities due to changes in underlying property markets. No employee count disclosed for this specific adjustment.
2007-10-31restructuringin_progress2005USD 12 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Multi-year plan launched in Q4 fiscal 2005 to cut workforce and facility footprint after semiconductor divestitures. Fiscal 2007 charge of $12M comprises $17M workforce-reduction expense offset by a $5M net release of the excess-facility accrual (sub-lease recovery improvement). Workforce-reduction component substantially complete at fiscal year-end with only $1M accrued; cash payments of $51M made in fiscal 2007 ($29M workforce, $22M facilities). Excess-facility payments expected to continue roughly four more years; no employee count disclosed for fiscal 2007 activity.
2007-10-31reduction_in_forcein_progressUSD 35 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML
Ongoing, independent business-realignment workforce actions (explicitly not a formal restructuring plan), each individually immaterial. Approximately $35M of workforce management charges incurred in fiscal 2007, with roughly $20M of additional charges expected in fiscal 2008. Company-wide; general infrastructure/shared services headcount fell about 230 during the year to approximately 2,500.
2007-10-31acquisition_additioncompleted2007-06-06Bio-analytical Measurement (life sciences)USD 252 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML
Date shown is the completion date per Note 13; the deal was first announced in Q2 fiscal 2007. Acquired Stratagene Corporation for approximately $252M in cash (100% of common shares and vested options). Headcount added through the acquisition was not disclosed; Stratagene contributed about 2% of bio-analytical segment revenue growth in fiscal 2007. Associated charge reflects the aggregate purchase price, not a severance charge.
2007-10-31restructuringin_progress2005-10-01GlobalCorporate-wide (2005 Plan)USD 17 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY2007 workforce-reduction expense of $17M under the 2005 Plan; total FY2007 restructuring charge was $12M (workforce $17M plus a $5M net release on excess facilities). Workforce-reduction component substantially complete with a $1M accrual remaining at year-end; facility-consolidation payments continue over the next four years. Employees affected in FY2007 not disclosed.
2007-10-31restructuringin_progress2008-10-31GlobalEnterprise-wide workforce management actionsUSD 35 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Independent workforce-management actions taken during FY2007 (not part of a formal restructuring plan), individually immaterial; approximately $35M incurred in 2007 with a further charge of approximately $20M expected in 2008. Employees affected not disclosed.
2007-10-31acquisition_additioncompleted2007-06-062007-06-06United StatesBio-Analytical Measurement (life sciences)USD 252 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Stratagene completed June 6, 2007 for approximately $252M cash; headcount added through the acquisition not disclosed. Purchase price shown for context, not a workforce charge.
2007-10-31restructuringin_progress2005-10-01GlobalAll segmentsUSD 12 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
2005 Plan restructuring charges of $12 million recorded in 2007. Workforce reduction component substantially complete; facility consolidation continues.
2007-10-31restructuringin_progress2005-10-01GlobalAll segmentsUSD 17 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Workforce reduction expenses of $17 million recorded in 2007 under the 2005 Plan.
2007-10-31acquisition_additioncompleted2007-06-01GlobalBio-analytical MeasurementMD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Acquisition of Stratagene Corporation completed in June 2007. Headcount increase predominantly due to acquisitions.
2007-10-31restructuringin_progressGlobalGeneral InfrastructureUSD 35 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Total workforce management charges of approximately $35 million incurred in 2007 for independent actions not constituting a formal restructuring plan.
2007-10-31restructuringcompleted2005-10-01WorldwideGeneral Infrastructure and Shared ServicesUSD 12 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
2005 Plan restructuring charges of $12 million in 2007. Workforce reduction expenses were $17 million. Workforce reduction component is substantially complete. General infrastructure headcount decreased by approximately 230 employees from one year ago.
2007-10-31othercompletedWorldwideVariousUSD 35 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
Total workforce management charges of approximately $35 million incurred in 2007 for independent actions not constituting a formal restructuring plan.
2007-07-31restructuringin_progress2005-10-012007-10-31GlobalEnterprise-wide (workforce alignment following semiconductor divestiture and Verigy spin-off)USD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY2005 Plan: $16M in charges for the nine months ended July 31, 2007 (zero in the quarter), mostly for individuals notified before October 31, 2006; about $1M of future charges expected. Restructuring accrual of $42M at quarter-end. Number of employees affected not disclosed in this filing.
2007-07-31restructuringin_progress2007-07-31GlobalEnterprise-wide workforce realignmentUSD 20 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Independent post-FY2005 workforce management actions (not a formal restructuring plan), each individually immaterial; approximately $20M total charges to date, majority recognized in the third quarter, with about $3M of future charges expected. Employee counts not disclosed.
2007-07-31acquisition_additioncompleted2007-06-062007-06-06United StatesBio-analytical Measurement (life sciences)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Stratagene Corp. closed June 6, 2007 for approximately $252M cash; headcount added through the acquisition not disclosed.
2007-07-31restructuringin_progress2005-10-012007-10-31GlobalVariousUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY2005 Plan charges incurred in the nine months ended July 31, 2007. Mostly associated with individuals notified prior to Oct 31, 2006. Completion expected by end of fiscal 2007.
2007-07-31restructuringin_progressGlobalVariousUSD 20 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0
Post-FY2005 Plan workforce management actions. Total charges expected approx $20 million, majority recognized in Q3. Future charges approx $3 million expected.
2007-04-30restructuringin_progress2007-10-31GlobalCompany-wideUSD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY2005 Plan announced in fiscal Q4 2005 (exact announcement date not disclosed) to align workforce with reduced revenue base after semiconductor divestiture and Verigy spin-off; voluntary and involuntary terminations. Charges of $7M in Q2 and $16M in the six months ended April 30, 2007; workforce-reduction accrual of $4M at April 30, 2007 (total restructuring accrual $48M including excess-facility component). Approximately $1M of additional charges expected for previously notified individuals; completion expected by end of fiscal 2007. No employee count disclosed.
2007-04-30restructuringin_progressGlobalCompany-wideUSD 3 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-FY2005 Plan workforce management actions; filer states these do not constitute a formal restructuring plan because each action is individually immaterial. Approximately $18M of workforce management charges expected over the next year, of which approximately $3M was recorded in Q2 2007. No employee count disclosed.
2007-04-30acquisition_additionannounced2007-04-052007-06-30United Statessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Definitive agreement to acquire Stratagene Corporation (La Jolla, California), a life sciences company, for $10.94 per share in cash, approximately $250M aggregate; expected to close in early June 2007. Headcount added not disclosed.
2007-04-30restructuringin_progress2005-10-012007-10-31USD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY2005 Plan charges for Q2 2007. Completion of workforce reduction expected by end of fiscal 2007.
2007-04-30restructuringin_progress2005-10-012007-10-31USD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY2005 Plan charges for YTD 2007. Completion of workforce reduction expected by end of fiscal 2007.
2007-04-30restructuringin_progressUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0
Workforce management charges recorded in Q2 2007, part of approx $18M expected over next year.
2007-01-31restructuringin_progress2007-10-31GlobalCorporate-wide (continuing operations)USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY2005 Plan workforce reduction announced in Q4 FY2005 to align workforce with smaller revenue base after semiconductor divestiture and Verigy spin-off; $9M charged in Q1 FY2007, mostly for individuals notified before 2006-10-31; approximately $5M of future charges expected; no employees-affected count disclosed; restructuring accrual was $58M at quarter-end
2007-01-31restructuringin_progress2005-10-012007-10-31GlobalWorkforce ReductionUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY2005 Plan charges incurred in Q1 2007 mostly associated with individuals notified prior to Oct 31, 2006. Completion expected by end of fiscal 2007.
2006-10-31restructuringin_progress2007Global (facility impairments primarily Germany and the US)General infrastructure / shared services primarily; FY2006 charges span cost of products and services, R&D, and SG&AUSD 186 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Program launched in Q4 fiscal 2005 to align workforce with smaller post-divestiture size; focused on shared-services cost reduction (target ~$450M infrastructure cost reduction, actions completed in FY2006). FY2006 charges of $186M comprise $111M workforce reduction, $33M excess facility consolidation, and $42M asset impairments; $172M in continuing operations ($28M COGS, $21M R&D, $123M SG&A) and $14M in Verigy discontinued operations. Severance accrual $13M at fiscal year-end (down from $44M); restructuring cash payments $166M in FY2006 (of which $142M workforce reduction severance). Workforce reduction expected substantially complete in fiscal 2007; lease payments on excess facilities continue approximately five more years. Employee headcount affected not explicitly disclosed; general infrastructure headcount fell ~1,160 year-over-year to ~2,750. Table aggregates Prior Plans (2001-2003), whose workforce reduction portion was completed in fiscal 2005.
2006-10-31divestiture_reductioncompleted2005-08-142005-12-01GlobalSemiconductor products businessdiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML
Sale to Avago Technologies Ltd. completed December 1, 2005 for approximately $2.6 billion cash ($2,559 million net of working capital adjustments); pre-tax gain on sale $1,816 million. Business reflected as discontinued operations for all periods; transferred employee headcount not disclosed.
2006-10-31divestiture_reductioncompleted2005-08-152006-10-31GlobalSemiconductor test solutions business (Verigy Ltd.)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML
Separation of Verigy into a stand-alone public company; IPO of approximately 8.7 million ordinary shares (~15% of outstanding) completed June-July 2006 for net proceeds of $121 million. Remaining 85% (~50 million shares) distributed to Agilent stockholders on October 31, 2006 via pro rata non-cash dividend reducing retained earnings by $310 million; market value of distributed shares approximately $840 million. Business reflected as discontinued operations; transferred employee headcount not disclosed.
2006-10-31restructuringin_progress2005-10-312007-10-31GlobalCorporate infrastructure and shared servicesUSD 111 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
2005 Plan workforce-reduction component; $111M of the $186M total FY2006 restructuring and asset impairment charges. Workforce accrual $13M at 2006-10-31 (down from $44M); workforce portion expected substantially complete in fiscal 2007. Employees affected not disclosed.
2006-10-31plant_closurein_progress2005-10-312011-10-31Germany and United StatesCorporate facilitiesUSD 33 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Excess-facility consolidation component of the same 2005 Plan; FY2006 expense also included $42M of asset impairment charges (primarily Germany and U.S. facilities), all within the $186M program total. Facility accrual $58M at year-end; lease payments expected to continue roughly five years.
2006-10-31divestiture_reductioncompleted2005-08-142005-12-01GlobalSemiconductor products businessdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Sale to Avago Technologies completed 2005-12-01 for ~$2.6B cash; headcount transferred not disclosed.
2006-10-31divestiture_reductioncompleted2005-08-152006-10-31GlobalSemiconductor test solutions business (Verigy)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Verigy separated 2006-06-01, IPO June-July 2006, remaining ~85% stake distributed to stockholders 2006-10-31; headcount removed not disclosed.
2006-10-31divestiture_reductioncompleted2005-08-122005-11-28GlobalLumileds Lighting joint venture (equity interest)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Sale of Agilent's ~47% stake to Philips for $949M plus $51M debt repayment; headcount impact not disclosed.
2006-10-31restructuringin_progress2005-10-012007-10-31GlobalGeneral Infrastructure and Shared ServicesUSD 186 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
2005 Plan launched in Q4 2005 to reduce workforce and facility footprint. In 2006, recorded $186 million in restructuring and asset impairment charges ($111 million for workforce reduction). Workforce reduction portion expected to be substantially completed in fiscal year 2007.
2006-10-31divestiture_reductioncompleted2005-08-152006-10-31GlobalSemiconductor Test Solutionsdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Spin-off of semiconductor test solutions business (Verigy) completed on October 31, 2006. Employees transferred to Verigy.
2006-10-31divestiture_reductioncompleted2005-08-142005-12-01GlobalSemiconductor Productsdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Sale of semiconductor products business to Avago completed in December 2005. Employees transferred to Avago.
2006-10-31restructuringin_progress2005-10-312007-10-31WorldwideGeneral Infrastructure and Shared ServicesUSD 186 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
2005 Plan launched in Q4 2005 to reduce workforce and facility footprint. Workforce reduction portion expected to be substantially completed in fiscal 2007. Includes $111M workforce reduction and $75M facility/impairment charges in 2006.
2006-10-31divestiture_reductioncompleted2005-08-142005-12-01WorldwideSemiconductor Productsdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0
Sale of semiconductor products business to Avago completed December 1, 2005. Headcount removed not explicitly quantified in employee count, but business reported as discontinued.
2006-10-31divestiture_reductioncompleted2005-08-152006-10-31WorldwideSemiconductor Test Solutionsdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0
Spin-off of Verigy (semiconductor test solutions) completed October 31, 2006. Headcount removed not explicitly quantified in employee count, but business reported as discontinued.
2006-07-31restructuringin_progress2005-10-312007-10-31GlobalCorporate-wide (workforce and excess facilities)USD 145 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY05 Plan announced in Q4 FY2005 to align workforce with smaller revenue base; nine-month charge of $145M comprises $95M workforce reduction, $24M excess facilities, $26M impairments. Execution of workforce component expected to complete during fiscal 2007; no employee count disclosed. Restructuring accrual was $76M at July 31, 2006.
2006-07-31divestiture_reductionin_progress2005-08-152006-10-31GlobalSemiconductor Test Solutions (Verigy Ltd.)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Spin-off of Verigy; IPO of 8.7M shares at $15 completed in Q3 FY2006, leaving Agilent with ~85% (~50M shares). Distribution of remaining shares expected by end of fiscal 2006; no headcount count disclosed. Separation date June 1, 2006.
2006-07-31divestiture_reductioncompleted2005-10-312005-12-01GlobalSemiconductor Products business (sold to Avago Technologies Ltd.)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Divestiture completed December 1, 2005 for ~$2,559M cash proceeds; results reported as discontinued operations for all periods. No employee count disclosed; action occurred in Q1 FY2006 but is described throughout this filing.
2006-07-31plant_closurecompleted2006-04-252006-10-31United States (Palo Alto and San Jose, California)Corporate facilities consolidationrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Sale of Palo Alto headquarters completed May 2006 ($98.5M consideration, $65M gain) with leaseback through move to Santa Clara campus in Q4 FY2006; San Jose site sold in Q2 FY2006 ($88M, $56M gain). Part of excess-facilities consolidation; no employee count disclosed.
2006-07-31restructuringin_progress2005-10-312007-10-31GlobalAll segmentsUSD 145 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY05 Plan launched in Q4 2005 to align workforce with smaller revenue base following semiconductor divestiture. Includes voluntary and involuntary terminations. Workforce reduction execution expected to complete in fiscal 2007. Total charges for nine months ended July 31, 2006 were $145 million ($95M workforce, $24M facilities, $26M impairments).
2006-04-30restructuringin_progress2006-10-31GlobalEnterprise-wide (workforce reduction component of FY05 Plan)USD 70 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY05 Plan workforce reduction component: $70M charge for six months ended April 30, 2006 ($70M of which is the total charge line); $81M cash payments made; accrual balance $33M at April 30, 2006. Voluntary and involuntary terminations; no employee count disclosed. Announced in Q4 FY2005 to align workforce with smaller revenue base after semiconductor products divestiture and planned STS spin-off.
2006-04-30restructuringin_progress2011-04-30GlobalFacilities / real estate (consolidation of excess facilities)USD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Facility consolidation component of FY05 Plan: $13M charge for six months ended April 30, 2006; accrual $50M at April 30, 2006; lease payments expected over next five years. Includes $22M impairment charges for two sites (one California, one Germany) recorded in Q2 FY2006. San Jose site sold in Q2 FY2006 for $88M consideration with $56M gain. No employee counts disclosed.
2006-04-30divestiture_reductioncompleted2005-12-01GlobalSemiconductor products business (sold to Avago Technologies Ltd.)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Divestiture completed December 1, 2005 for approximately $2,565M cash proceeds; results reported as discontinued operations for all periods. Headcount removed through the sale is not disclosed.
2006-04-30divestiture_reductionannounced2005-08-152006-10-30GlobalSemiconductor test solutions (Verigy)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Spin-off announced August 15, 2005; separation agreements dated May 31/June 1, 2006 set a June 1, 2006 separation date; distribution of Agilent shares in Verigy expected complete by end of fiscal 2006, subject to conditions. Headcount transferring with the business is not disclosed. Related separation costs of $65M for six months ended April 30, 2006 (per segment reconciliation).
2006-04-30restructuringin_progress2005-10-312006-10-31GlobalCorporate / Shared ServicesUSD 105 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY05 Plan launched in Q4 2005 to align workforce with smaller revenue base following semiconductor products divestiture. Includes voluntary and involuntary terminations. Expected completion by end of fiscal 2006. Total charge of $105M for six months ended April 30, 2006 includes $70M workforce reduction, $13M facility consolidation, and $22M asset impairments.
2006-01-31restructuringin_progress2005-102006-10-31GlobalEnterprise-wide (voluntary and involuntary terminations)USD 39 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
FY05 Plan launched in fiscal Q4 2005 to align workforce with smaller organization after semiconductor products divestiture and planned semiconductor test spin-off; $39M charge recorded in the quarter, all for workforce reduction; no employee count disclosed; restructuring accrual $80M at quarter-end ($37M workforce, $43M excess facilities)
2006-01-31divestiture_reductioncompleted2005-102005-12-01GlobalSemiconductor products businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Divestiture of semiconductor products business to Avago Technologies completed December 1, 2005 for approximately $2,579 million cash proceeds; no headcount transferred disclosed; related infrastructure headcount transfers to Avago referenced in MD&A without counts
2006-01-31divestiture_reductionannounced2005-102006-10-31GlobalSemiconductor Test Solutions (SOC and memory test)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Planned spin-off of semiconductor test solutions business by end of fiscal 2006 announced in fiscal Q4 2005; no employee count or spin-off related charge disclosed
2006-01-31restructuringin_progress2005-10-312006-10-31GlobalCorporate / All SegmentsUSD 39 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
FY05 Plan launched in Q4 2005 to align workforce with smaller organizational size following semiconductor products divestiture. Consists of voluntary and involuntary terminations. Expected to be completed by end of fiscal 2006. $39M charge recorded in Q1 2006.
2005-10-31restructuringin_progress6002006-10-31Worldwide (global infrastructure organization)General infrastructure and shared services (e.g., finance, IT, workplace services)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
FY05 Plan infrastructure component, initiated during fiscal Q4 2005: ~600 of ~1,300 targeted infrastructure jobs notified by fiscal year-end, with ~700 more expected in fiscal 2006. Note 14 reports a combined FY05 Plan workforce-reduction charge of $96 million for fiscal 2005 ($52 million cash paid; $44 million accrued), not split by component; plan completion estimated at end of fiscal 2006.
2005-10-31restructuringin_progress9002006-10-31Semiconductor test solutions: U.S., Germany, Japan; electronic measurement: U.S., U.K.Semiconductor test solutions and electronic measurement businessesrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML
FY05 Plan business-segment component: all ~900 segment job reductions notified as of October 31, 2005. Combined FY05 Plan program accounted for ~1,500 employees reduced or notified by fiscal year-end, with the $96 million fiscal-2005 workforce-reduction charge disclosed at program level in Note 14.
2005-10-31divestiture_reductioncompleted6,5002005-082005-12Asia, U.S., EuropeSemiconductor products businessMD&A
f5-10k / GLM-5.3-flash-HTML
Board approved divestiture in August 2005; asset sale to Avago Technologies Ltd. for approximately $2.66 billion completed December 2005 ($2.579 billion cash proceeds per Note 24). Includes approximately 6,500 regular employees transferring; ~200 additional infrastructure employees expected to move to the divested business in 2006. Option vesting was accelerated for that business's employees ($8 million charge in discontinued operations).
2005-10-31divestiture_reductionannounced2005-08-152006-10-31Semiconductor test solutions business (SOC, SIP and memory test)Item_1_Business
f5-10k / GLM-5.3-flash-HTML
Spin-off via IPO announced August 15, 2005; IPO expected near mid-year 2006 and spin-off completion by end of fiscal 2006. Semiconductor test solutions segment employed ~1,600 at fiscal year-end 2005; a separate headcount-transfer figure is not disclosed.
2005-10-31restructuringcompleted16,3002001U.S., Korea, Japan, U.K. and other countries (~116 facilities exited)All segments except bio-analytical measurement, plus infrastructure support servicesUSD 27 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
2001/2002/2003 restructuring plans ('Prior Plans'); workforce-reduction portion completed mid-2005. Employee count is cumulative through fiscal year-end (plan inception through FY2005); fiscal-2005-specific reduction count not separately disclosed. Fiscal 2005 charges of $27 million ($10M workforce, $10M excess facilities, $7M asset impairment); excess-facilities consolidation expected to complete within five years.
2005-10-31divestiture_reductioncompleted2005-02Camera module businessdiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML
Camera module business sold in February 2005; results reported within discontinued operations alongside the semiconductor products business. Headcount impact not disclosed.
2005-10-31restructuringin_progress6002006-10-31GlobalCorporate infrastructure (finance, IT, workplace services)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY05 Plan targets about 1,300 infrastructure jobs; approximately 600 employees notified by 2005-10-31, remaining 700 to be notified during fiscal 2006. Announced during fiscal Q4 2005 (exact date not disclosed). FY05 Plan total workforce charge of $96 million for fiscal 2005 is not allocated between sub-components.
2005-10-31restructuringin_progress9002006-10-31United States, Germany, Japan, United KingdomSemiconductor Test Solutions and Electronic Measurementrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
All approximately 900 segment positions notified by 2005-10-31; semiconductor test reductions focused in the U.S., Germany and Japan, electronic measurement reductions in the U.S. and U.K. FY05 Plan total workforce charge of $96 million for fiscal 2005 covers both sub-components.
2005-10-31restructuringcompleted16,3002005-06-30GlobalAll segmentsUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Headcount is cumulative through fiscal year-end across the 2001-2003 plans, not fiscal 2005-only; workforce-reduction portion completed mid-2005. Charge shown is the fiscal 2005 workforce-reduction charge only (Prior Plans total fiscal 2005 charge was $27 million including $10 million facilities and $7 million impairment).
2005-10-31plant_closurein_progress2010-10-31United States, South Korea, Japan, United Kingdom and other countriesAll segmentsUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Approximately 116 production, support and sales facilities exited (over 4.6 million square feet, about 24% of worldwide property) is cumulative through fiscal year-end; charge shown is the fiscal 2005 lease-termination charge. Facility portion expected to complete within five years; no affected-employee count disclosed.
2005-10-31divestiture_reductioncompleted6,5002005-08-142005-12-01Asia, United States, EuropeSemiconductor Products business (discontinued operation)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Approximately 6,500 regular employees transferred with the divestiture, completed after fiscal year-end. About 200 general infrastructure and shared services employees were expected to move to the divested business in 2006.
2005-10-31divestiture_reductionannounced1,6002005-08-152006-10-31GlobalSemiconductor Test Solutions (SOC, SIP and memory test)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Planned spin-off via IPO rather than a headcount reduction; affected count equals segment headcount at 2005-10-31. Expected completion by end of fiscal 2006.
2005-10-31divestiture_reductioncompleted2005-08-122005-11-28GlobalLumileds joint venture (47% interest)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Sale of Agilent's Lumileds stake to Philips completed after fiscal year-end; no employee count disclosed for the joint venture.
2005-10-31restructuringin_progress1,5002005-10-312006-10-31GlobalInfrastructure and Business SegmentsMD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
FY05 Plan initiated in Q4 2005. Includes ~600 infrastructure employees notified by year-end and ~900 segment employees notified by year-end. Total estimated reduction is ~1,500. Completion expected by end of fiscal 2006.
2005-10-31divestiture_reductioncompleted6,5002005-08-152005-12-31GlobalSemiconductor Productssubsequent_events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Sale of semiconductor products business to Avago completed in December 2005. Divestiture includes approximately 6,500 regular employees.
2005-10-31restructuringin_progress1,3002005-10-312006-10-31GlobalInfrastructureItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0
FY05 Plan: Reduce infrastructure-related employment by about 1,300 jobs. As of Oct 31, 2005, 600 notified; 700 expected in FY2006.
2005-10-31restructuringcompleted9002005-10-312005-10-31GlobalSemiconductor Test Solutions; Electronic MeasurementItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0
FY05 Plan: Job reductions within business segments. All 900 notified as of Oct 31, 2005.
2005-10-31divestiture_reductioncompleted6,5002005-12-012005-12-01GlobalSemiconductor ProductsItem_7_MD&A
f5-10k / Qwen3.6-27B-Q8_0
Sale of semiconductor products business to Avago completed Dec 2005. Includes approx 6,500 regular employees.
2005-07-31restructuringin_progressGlobalEnterprise (plans announced 2001, 2002, 2003)USD 54 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Total charge for nine months ended July 31, 2005; workforce reduction accrual balance was $25M at quarter-end, expected to be paid within 12 months. Substantially all workforce actions under prior plans completed; facility consolidation charges continue for five years. No employee counts disclosed.
2005-07-31voluntary_separationin_progressGlobalTest and Measurementrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Voluntary Severance Program disclosed alongside traditional workforce reductions in test and measurement; no participant count or separate charge disclosed
2005-07-31restructuringannounced2005-08-152006-10-31GlobalCorporate infrastructureUSD 200 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Plan to cut infrastructure costs by more than $450M and about 1,300 infrastructure jobs via transfers, attrition and workforce reductions; also eliminates approximately 11 facilities, primarily tied to the semiconductor products sale. Implementation costs may be offset by asset sale proceeds; facility consolidation charges still under evaluation. Substantially complete by end of fiscal 2006.
2005-07-31divestiture_reductionannounced2005-08-142005-10-31GlobalSemiconductor Productssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Agreement to sell semiconductor products business to Argos Acquisition Pte. Ltd. for $2.66B, subject to adjustment and antitrust approvals; expected to close around fiscal year-end. No headcount disclosed; segment had net assets of $556M at July 31, 2005. Company will retain designated tax, environmental and warranty contingencies.
2005-07-31divestiture_reductionannounced2005-08-12GlobalLumileds Lighting joint venturesubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Sale of Agilent's Lumileds stake to Philips for $948.5M plus repayment of about $51M debt; joint venture agreements terminate at closing. Carrying value of investment was about $40M at July 31, 2005. Subject to antitrust approval; no headcount disclosed.
2005-07-31divestiture_reductionannounced2005-08-152006-10-31GlobalAutomated Test — SOC and memory test businessessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Planned spin-off of SOC and memory test businesses as soon as practical in fiscal 2006; considering IPO of about 19% followed by distribution of remaining 81% to shareholders. Businesses had $192M revenue in Q3 FY2005, of which SOC and memory test was about 60%. No headcount disclosed.
2005-07-31restructuringin_progress2005-08-152006-10-31GlobalInfrastructureUSD 200 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0
Announced plan to reduce infrastructure costs by >$450M and infrastructure-related employment by about 1,300 jobs. Includes ~$200M implementation costs. Substantially complete by end of fiscal 2006.
2005-07-31voluntary_separationin_progressTest and MeasurementTest and Measurementrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Workforce reduction charges relating to a Voluntary Severance Program in the test and measurement business.
2005-04-30restructuringin_progressGlobalEnterpriseUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Covers the 2001 Plan and 2003 Plan, both winding down; charge is for the six months ended April 30, 2005 (three-month charge was $6 million). No employee counts disclosed; includes workforce reduction, excess facility consolidation and asset impairment components. Severance-type payments expected primarily within the next two quarters; lease payments over the next 5 years.
2005-04-30divestiture_reductioncompleted2005-02-032005-02-03GlobalSemiconductor Products (camera module business)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Sale of camera module business completed February 3, 2005; historical segment amounts restated to exclude it. No headcount associated with the divestiture disclosed.
2005-04-30plant_closurecompletedUnited States (Rohnert Park, California)Manufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Manufacturing site sold during the quarter ended April 30, 2005; site had been previously impaired under the 2003 Plan. A $10 million gain was recorded in cost of products and services. No employee count disclosed.
2005-04-30restructuringannouncedAsia / United KingdomSemiconductor Products (navigation business; UK R&D site)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Company is moving its navigation business to Asia and closing a research and development site in the United Kingdom; no headcount figures or timing disclosed.
2005-04-30restructuringin_progressAsiaAutomated TestMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Automated test divisions being combined for efficiencies; management and R&D project teams plus a significant portion of outsourced manufacturing test moving to Asia. No headcount figures disclosed.
2005-04-30restructuringin_progressUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Total charge of $13 million for the six months ended April 30, 2005, relating to the '2001 Plan' and '2003 Plan'. Plans are winding down; workforce reduction charges expected to continue for announced but not completed plans.
2005-04-30plant_closurecompletedRohnert Park, Californiarestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Sold a manufacturing site previously impaired under the 2003 Plan. Recorded a gain of $10 million.
2005-04-30plant_closurein_progressUnited KingdomSemiconductor ProductsMD&A
f5-10q / Qwen3.6-27B-Q8_0
Closing a research and development site in the United Kingdom.
2005-01-31restructuringin_progress2005-10-31USD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Covers the 2001 Plan and 2003 Plan wind-down; workforce reduction charge of $6M in the quarter (total restructuring and asset impairment charge $7M including $1M asset impairment). No employee counts disclosed; further workforce reduction charges expected through fiscal 2005, with lease payments over the next 5 years. Severance accrual balance was $12M at January 31, 2005.
2005-01-31divestiture_reductioncompleted2004-10-272005-02-03Semiconductor ProductsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Sale of the camera module business to Flextronics completed February 3, 2005; business represented about 15% of the segment's fiscal 2004 orders and revenue. No headcount impact disclosed; Agilent remains in the image sensor business.
2005-01-31voluntary_separationannounced12005-03-082005-04-01United StatesSemiconductor ProductsUSD 1 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Settlement with Young K. Sohn, SVP and President of the Semiconductor Products Group, providing severance of $1,083,750 (18 months of base plus target short-term incentive) on voluntary termination; Dick Chang to lead the group on an interim basis.
2005-01-31restructuringin_progress2001-10-01USD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Activity related to 2001 Plan and 2003 Plan. Total charge of $7 million recorded in Q1 2005. Key actions executed, plans winding down. Lease payments expected over next 5 years.
2004-10-31restructuringin_progress5,8002003-02-212005-06-30Primarily U.S. operationsAll businesses; significant reductions in test and measurement and semiconductor productsUSD 101 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Headcount is cumulative under the plan through fiscal 2004 (plan originally announced about 4,000 additional job cuts). FY2004 plan charges totaled $154M, of which $101M was workforce reduction (captured here); the remainder was $28M excess-facility consolidation and $25M asset impairment (see separate plant-closure record). Cumulative plan cost $462M through Oct 31, 2004; substantially complete with residual charges expected in H1 fiscal 2005; plan restructuring accrual was $44M at fiscal year-end.
2004-10-31plant_closurein_progress2004California, United StatesTest and Measurement (primarily)USD 25 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Exit of a manufacturing site announced during fiscal Q2 2004 (Feb–Apr 2004); FY2004 asset impairment of $25M primarily related to this site (within the 2003 Plan's FY2004 charges — do not sum with the plan's $101M workforce charge). Additional impairment possible upon sale of the site; affected headcount not disclosed.
2004-10-31restructuringcompleted2,5002002-08-19All regionsPrimarily test and measurement (wireline manufacturing/field operations) and semiconductor products; also IT support servicesUSD 0 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Plan complete as of fiscal 2004. The 2,500-employee reduction was executed in fiscal 2002–2003; no new charges in FY2004, only $14M of residual severance cash payments. Cumulative plan cost $166M through Oct 31, 2004.
2004-10-31restructuringcompleted2001U.S., Korea, Japan, U.K. and other countries (facility exits)Primarily test and measurement and semiconductor products; support-services reductions across all businessesUSD 7 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Initiated in fiscal Q4 2001 (Aug–Oct 2001); all key actions executed; no separate headcount disclosed for this plan. FY2004 activity was $7M of net charges from consolidating excess facilities (reduced estimated sublease income) — no workforce charges in FY2004. Cumulative plan cost $533M through Oct 31, 2004. Across all three plans, the company exited more than 115 production, support and sales facilities (over 4.6 million square feet, about 24% of worldwide property).
2004-10-31acquisition_additioncompleted2004-10-28Life Sciences and Chemical Analysisbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML
Acquisition of Silicon Genetics (life-science software) completed October 2004; about 772 thousand shares (~$18M) issued as consideration and ~$16M goodwill added in the Life Sciences segment. Acquired headcount not disclosed. One of three FY2004 acquisitions, all described by the filer as not significant.
2004-10-31divestiture_reductionin_progress2004Semiconductor Products (camera module business)MD&A
f5-10k / GLM-5.3-flash-HTML
Agreement reached in fiscal Q4 2004 (Aug–Oct 2004) to sell camera-module inventory and fixed assets; sale pending as of the December 2004 filing date. Agilent will retain image-sensor intellectual property and continue selling image sensors but will cease producing assembled modules. Affected headcount not disclosed; FY2004 camera-module revenue was ~$300M and FY2004 included a $20M inventory charge related to this business.
2004-10-31restructuringin_progress5,8002003-02-21Primarily United StatesAll businesses, with significant reductions in Test and Measurement and Semiconductor ProductsUSD 154 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Cumulative through fiscal year-end 2004 (plan announced Feb 2003; total plan cost $462M, of which $308M in FY2003 and $154M in FY2004). FY2004 charges comprise $101M workforce reduction, $28M excess-facility consolidation and $25M asset impairment (California manufacturing site). Restructuring accrual for all plans was $87M at 2004-10-31.
2004-10-31plant_closurein_progress2001-10-31United States, Korea, Japan, United Kingdom and other countriesAll segments — production, support and sales facilitiesUSD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Cumulative through fiscal year-end 2004: more than 115 facilities exited representing over 4.6 million sq ft (~24% of worldwide property); total plan cost $533M ($154M in 2001, $357M in 2002, $15M in 2003, $7M in 2004). All key actions executed; lease payments continue over next five years. FY2004 charge reflects reduced sublease income estimates.
2004-10-31restructuringcompleted2002-08-192004-10-31All regionsManufacturing and field operations serving wireline markets (Test and Measurement) and IT support servicesUSD 0 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Plan complete; no charges recorded in FY2004. Announced intention to reduce workforce by 2,500 to reach ~$1.6B quarterly operating cost structure. Cumulative plan cost $166M ($117M in 2002, $49M in 2003).
2004-10-31divestiture_reductionannounced2004-10-27Not specifiedSemiconductor Products — camera module businessMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Agreement dated 2004-10-27 with Flextronics Sales and Marketing (A-P) Ltd. to sell inventory and fixed assets of the camera module business (~$300M of 2004 revenue). Agilent retains image sensor IP and R&D. Not expected to materially affect 2005 operating profits; no employee count disclosed.
2004-10-31acquisition_additioncompleted2004-10-282004-10-28Not specifiedLife Sciences and Chemical Analysis — software and informaticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquired Silicon Genetics; 771,573 shares of Agilent common stock issued (approx. $18M value) as consideration. Adds GeneSpring, Varia and GeNet products. No employee count disclosed; acquisition immaterial to consolidated results.
2004-10-31acquisition_additioncompletedNot specifiedAutomated Test — flat panel display test businessMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Entered the flat panel display test market through acquisition of IBM's flat panel display business during FY2004. No announcement date or employee count disclosed; three acquisitions in 2004 were immaterial individually and in aggregate.
2004-10-31restructuringcompleted2001-10-01WorldwideAll segmentsUSD 7 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
2001 Plan. Key actions executed. $7 million in net charges recorded in 2004 primarily due to reductions in estimated sublease income.
2004-10-31restructuringcompleted2002-10-01WorldwideAll segmentsUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
2002 Plan. Complete. No charges in 2004.
2004-10-31restructuringin_progress2003-02-21WorldwideAll segmentsUSD 154 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
2003 Plan. $154 million in charges recorded in 2004 ($101M workforce, $25M asset impairment, $28M facility consolidation). Plan substantially complete.
2004-10-31restructuringcompleted2001-10-01GlobalAll segmentsUSD 7 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
2001 Plan. Key actions executed. $7 million in net charges/adjustments recorded in FY2004 primarily for facility consolidation.
2004-10-31restructuringcompleted2002-10-01GlobalAll segmentsUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
2002 Plan. Complete. No charges recorded in FY2004.
2004-10-31restructuringin_progress2003-02-212005-04-30GlobalAll segmentsUSD 154 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
2003 Plan. $154 million total charge in FY2004 ($101M workforce, $28M facilities, $25M asset impairment). Substantially complete, with further costs expected in first half of FY2005.
2004-07-31restructuringin_progress5,6002003-02-21Primarily United StatesAll segments; reductions concentrated in Test and Measurement and Semiconductor Products, plus support functionsUSD 100 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Employee count is cumulative since the February 2003 announcement, not a quarterly figure. Plan described as substantially complete with additional charges expected in Q4 2004. Nine-month charge of $100M comprises $70M workforce reduction, $14M excess facilities, $16M asset impairment. Restructuring accrual for all plans was $75M at July 31, 2004.
2004-07-31plant_closurein_progressKobe, JapanProduction facility (2001 Plan — consolidation of excess facilities)USD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Nine months ended July 31, 2004 additional charge primarily related to sale of the Kobe production facility; no employee count disclosed. 2001 Plan accrual balance was $52M at July 31, 2004 with lease payments continuing over the next five years.
2004-07-31restructuringin_progress2001-10-01GlobalTest and Measurement; Semiconductor ProductsUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2001 Plan. Key actions executed. Additional $7M charge in nine months ended July 31, 2004 primarily relating to sale of production facility in Kobe, Japan. Lease payments continue over next five years.
2004-07-31restructuringcompleted2002-10-01GlobalTest and Measurement; Semiconductor Products; IT SupportUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2002 Plan. Target workforce reduction of 2,500 achieved as of July 31, 2004. Plan is complete. Zero charges in 2004.
2004-07-31restructuringin_progress2003-02-21GlobalAll BusinessesUSD 100 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2003 Plan. Announced Feb 21, 2003. Workforce reduced by approx 5,600 as of July 31, 2004. Total charges for nine months ended July 31, 2004 were $100M ($70M workforce, $14M facilities, $16M asset impairment). Plan substantially complete, additional charges expected in Q4.
2004-04-30restructuringin_progress5,2002003-02-21Primarily United StatesAll businesses; significant reductions in test and measurement and semiconductor products groupsUSD 58 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced intent to cut about 4,000 jobs; actual reduction approximately 5,200 as of April 30, 2004. Charge of $58M is the six months ended April 30, 2004 total ($46M workforce, $8M facilities, $4M asset impairment); cumulative plan cost $366M. Expected $125M quarterly cost reduction already realized; further charges expected through 2004, completion date not disclosed.
2004-04-30restructuringin_progressUnited States, Korea, Japan, United Kingdom and other countriesTest and measurement and semiconductor products groups, plus shared support servicesUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Plan initiated in fiscal Q4 2001; exact announcement date not disclosed. Key actions executed; remaining activity is excess-facility consolidation. Charge is the six months ended April 30, 2004 adjustment for reduced expected sublease income. Cumulative plan cost $533M; lease payments continue for about five years.
2004-04-30restructuringcompleted2,5002002-08-19All regionsManufacturing and field operations serving wireline markets within test and measurement, plus information technology support servicesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Plan complete; no charges recorded in fiscal 2004. Cumulative plan cost $166M; remaining $14M accrual paid down to zero during the six months ended April 30, 2004.
2004-04-30plant_closureannouncedRohnert Park, California, United StatesTest and Measurement (manufacturing site)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced during the second quarter of fiscal 2004 (exact date not disclosed); production to be transferred to other company sites. Filer anticipates further asset impairment charges but does not quantify them or disclose affected-employee counts.
2004-04-30restructuringin_progress2001-10-01GlobalTest and Measurement; Semiconductor ProductsUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2001 Plan. Additional $7 million charge recorded in six months ended April 30, 2004 due to reductions in estimate of expected sublease income.
2004-04-30restructuringcompleted2002-10-01GlobalTest and Measurement; Semiconductor ProductsUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2002 Plan. Plan is complete. Zero charge in 2004.
2004-04-30restructuringin_progress2003-02-21GlobalAll segmentsUSD 58 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2003 Plan. Total charge of $58 million for six months ended April 30, 2004, comprising $46 million workforce reduction, $8 million consolidation of excess facilities, and $4 million asset impairment.
2004-01-31restructuringin_progressUnited States, Korea, Japan, United Kingdom and other countriesPrimarily Test and Measurement and Semiconductor Products; support services across all businessesUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
2001 Plan initiated in fiscal Q4 2001; cumulative cost through 2004-01-31 was $533 million. All key actions executed, but facility consolidation continues with lease payments over the next five years. Q1 FY04 charge of $7 million reflected a reduction in estimated sublease income. Cumulative workforce reduction across all three plans was approximately 16,000 people (approximately 14,400 involuntary and approximately 1,600 net attrition).
2004-01-31restructuringcompleted2,5002002-08-19All regionsManufacturing and field operations serving wireline markets within Test and Measurement; information technology support servicesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced intention to reduce workforce by 2,500 to reach a quarterly operating cost structure of approximately $1.6 billion. Approximately 2,500 positions reduced as of 2004-01-31 (cumulative since announcement, not quarterly). Plan described as substantially complete; no charge recorded in Q1 FY04. Cumulative cost through 2004-01-31 was $166 million.
2004-01-31restructuringin_progress5,0002003-02-21Primarily United StatesAll businesses, with significant reductions in Test and Measurement and Semiconductor Products; research and development and support functionsUSD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced workforce reduction of approximately 4,000 jobs in addition to prior cuts, targeting quarterly operational costs of $1.45 billion. Approximately 5,000 positions reduced as of 2004-01-31 (cumulative since announcement, not quarterly). Q1 FY04 charge of $38 million comprised $31 million workforce reduction, $4 million facility consolidation and $3 million asset impairment. Cumulative cost through 2004-01-31 was $346 million. Company reports achieving its $1.4 billion quarterly operating cost target three quarters early.
2004-01-31plant_closurein_progressUnited States, Korea, Japan, United Kingdom and other countriesProduction, support and sales facilities across all segmentsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
More than 110 production, support and sales facilities exited, representing more than 3.8 million square feet (about 20 percent of worldwide property). Cumulative across all plans, not a quarterly figure; lease payments continue over the next five years. Restructuring accrual was $94 million at 2004-01-31 versus $89 million at 2003-10-31.
2004-01-31restructuringin_progress2001-10-01GlobalTest and Measurement; Semiconductor ProductsUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2001 Plan. Charge due to reductions in estimate of expected sublease income. Plan substantially complete but lease payments continue.
2004-01-31restructuringcompleted2002-10-01GlobalTest and Measurement; Semiconductor ProductsUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2002 Plan. Substantially complete. No charges in Q1 2004.
2004-01-31restructuringin_progress2003-02-21GlobalAll segmentsUSD 38 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2003 Plan. Includes $31M workforce reduction, $4M facility consolidation, $3M asset impairment. Cumulative reduction of approx 5,000 jobs as of Jan 31, 2004.
2003-10-31restructuringcompleted8,4002001Primarily test and measurement and semiconductor products; support-services reductions across all businessesUSD 526 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Cumulative through fiscal year-end since plan initiation in fiscal Q4 2001; risk-factor narrative separately cites approximately 8,000 positions announced in calendar 2001. Total cost of $526 million through October 31, 2003, of which $15 million was recorded in FY2003, primarily facility-consolidation adjustments. All key actions executed; lease payments on exited space continue for up to five years. Workforce reduction charges were $117 million (FY2001) and $175 million (FY2002).
2003-10-31restructuringin_progress2,4002002-08-192004-01-31All regionsManufacturing and field operations serving wireline markets (primarily test and measurement) and information technology support services; most segments affectedUSD 166 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Plan announced targeting 2,500 positions to reach a ~$1.6 billion quarterly cost structure; approximately 2,400 reduced as of October 31, 2003 (cumulative through fiscal year-end). Total cost of $166 million, including $49 million recorded in FY2003 (workforce charges of $83 million in FY2002 and $44 million in FY2003). Filer describes the plan as substantially complete, with completion expected by fiscal Q1 2004 (quarter ending January 31, 2004).
2003-10-31restructuringin_progress4,3002003-02-21Primarily United StatesAll businesses; largest reductions in test and measurement and semiconductor products, plus production facilities, support services and R&DUSD 308 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Announced reduction of approximately 4,000 jobs to reach a $1.45 billion quarterly cost structure; approximately 4,300 reduced as of October 31, 2003. FY2003 charge of $308 million comprises $238 million workforce reduction, $13 million excess-facility consolidation and $57 million asset impairment ($234 million of workforce severance paid in cash during FY2003). Plan still being implemented; further costs expected in the first half of fiscal 2004, with the expected $125 million quarterly cost reduction already being realized.
2003-10-31plant_closurein_progressU.S., Korea, Japan, U.K. and other countriesProduction, support and sales facilitiesrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Cumulative across the 2001, 2002 and 2003 restructuring plans: more than 110 production, support and sales facilities exited or planned for exit, representing more than 4.3 million square feet (about 22 percent of worldwide property); approximately 90 percent vacated as of October 31, 2003, with lease payments continuing for up to five years. Facility-consolidation charges (e.g., $13 million in FY2003 under the 2003 Plan) are included in the plan-level charges reported above. Includes a U.K. production facility closed in fiscal Q3 2003, with a related $27 million impairment driven by the U.K. property market decline.
2003-10-31restructuringcompleted8,4002001GlobalPrimarily test and measurement and semiconductor products; all support functionsUSD 15 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Cumulative program: 8,400 jobs reduced since inception; FY2003 charge of $15M is the current-year portion of $526M cumulative cost. All key actions executed; lease payments continue through 2008.
2003-10-31restructuringin_progress2,4002002-08-192004-03-31GlobalManufacturing and field operations serving wireline markets (test and measurement); IT support servicesUSD 49 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
2,500 announced; 2,400 reduced as of 2003-10-31 (cumulative since Aug 2002 announcement). FY2003 charge of $49M is current-year portion of $166M cumulative cost. Target: $1.6B quarterly operating cost structure.
2003-10-31restructuringin_progress4,3002003-02-21Primarily United StatesAll businesses, with significant reductions in test and measurement and semiconductor products; R&D and support functionsUSD 308 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Approximately 4,000 announced; 4,300 reduced as of 2003-10-31. Charge comprises $238M workforce, $13M facilities, $57M asset impairment. Target: $1.45B quarterly operational costs; further charges expected in first half of 2004.
2003-10-31plant_closurein_progressUnited States, Korea, Japan, United Kingdom and other countriesProduction, support and sales facilities across all segmentsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
More than 110 facilities exited or planned for exit, representing over 4.3 million square feet (~22% of worldwide property); approximately 90% vacated as of 2003-10-31, with lease payments continuing for up to five years. No separate employee count disclosed for closures.
2003-10-31othercompleted7,0002003-10-31GlobalCompany-wideItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Approximately 7,000 employees left the company during FY2003 (including ~1,000 in Q4), encompassing workforce reductions, attrition, divestitures and other departures; overlaps with the restructuring plans above.
2003-10-31restructuringcompleted8,4002001-10-01WorldwideAll segmentsUSD 154 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
2001 Plan: Announced in Q4 2001. Reduced workforce by approximately 8,400 jobs. Total cost through Oct 31, 2003 was $526 million, with $154 million charged in 2001. Key actions executed.
2003-10-31restructuringcompleted2,4002002-08-192004-01-31WorldwideTest and Measurement, Semiconductor Products, IT SupportUSD 117 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
2002 Plan: Announced Aug 19, 2002. Reduced workforce by approx 2,400 as of Oct 31, 2003. Total cost through Oct 31, 2003 was $166 million, with $117 million charged in 2002. Substantially complete.
2003-10-31restructuringin_progress4,3002003-02-21WorldwideAll segmentsUSD 308 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
2003 Plan: Announced Feb 21, 2003. Reduced workforce by approx 4,300 as of Oct 31, 2003. Total cost through Oct 31, 2003 was $308 million. Still being implemented.
2003-10-31restructuringcompleted13,4002001-10-012003-10-31GlobalAll segmentsUSD 372 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0
Cumulative involuntary terminations of approx. 13,400 people across 2001, 2002, and 2003 plans. Total restructuring charges for FY2003 were $372 million.
2003-10-31restructuringcompleted4,3002003-02-212003-10-31GlobalTest and Measurement, Semiconductor ProductsUSD 308 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0
2003 Plan announced Feb 21, 2003. Reduced workforce by approx. 4,300 as of Oct 31, 2003. Cost of plan was $308 million.
2003-10-31restructuringcompleted2,4002002-08-192003-10-31GlobalTest and Measurement, Semiconductor ProductsUSD 166 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0
2002 Plan announced Aug 19, 2002. Reduced workforce by approx. 2,400 as of Oct 31, 2003. Cost of plan through Oct 31, 2003 was $166 million.
2003-10-31restructuringcompleted8,4002001-10-012003-10-31GlobalTest and Measurement, Semiconductor ProductsUSD 526 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0
2001 Plan announced Q4 2001. Reduced workforce by approx. 8,400 jobs. Cost of plan through Oct 31, 2003 was $526 million.
2003-07-31restructuringin_progress3,4002003-02-212003-10-31Global (primarily United States)All businesses; significant reductions in test and measurement and semiconductor products, including research and developmentUSD 255 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Plan announced a workforce reduction of approximately 4,000 jobs; approximately 3,400 reduced as of July 31, 2003. Total charge of $255 million through July 31, 2003 includes $196 million workforce reduction, $7 million excess-facility consolidation and $52 million asset impairments. Company expects to fully achieve the $125 million quarterly cost reduction by end of fiscal 2003. Approximately 2,400 people left the company during the third quarter of 2003.
2003-07-31restructuringin_progress2,2002002-08-19Global (all regions)Manufacturing and field operations serving wireline markets within test and measurement; information technology support servicesUSD 160 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Plan announced a reduction of 2,500 jobs to reach a quarterly operating cost structure of approximately $1.6 billion; approximately 2,200 reduced as of July 31, 2003. Charge of $160 million total through July 31, 2003 ($117 million in fiscal 2002, $43 million in fiscal 2003). MD&A states significantly all savings have been achieved but the plan is not yet complete.
2003-07-31plant_closurein_progress300United KingdomSemiconductor Products (fabrication facility; production transferred to Singapore)USD 33 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Additional restructuring action announced during the third quarter of fiscal 2003: closure of a U.K. fabrication facility eliminating approximately 300 jobs, with production transferred to Singapore and the site in sale negotiations. Note 11 discloses a $33 million impairment on the U.K. property in the third quarter (an asset impairment within the 2003 Plan's $52 million impairment total). Exact announcement date not disclosed; incremental savings expected in fiscal Q4 2003 and fiscal Q1 2004. The 300 positions may be included within the 3,400 reductions reported under the 2003 Plan.
2003-07-31restructuringcompleted8,40020012002-10-31Global (U.S., Korea, Japan, U.K. and other countries)Primarily test and measurement and semiconductor products; manufacturing, selling, general and administrative functionsUSD 527 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Workforce reduction of approximately 8,400 jobs substantially completed by the end of fiscal 2002; MD&A states the plan is complete and continues to deliver approximately $300 million per quarter in savings. Charge of $527 million total through July 31, 2003 ($154 million in 2001, $357 million in 2002, $16 million in fiscal 2003). Company continues facility consolidation, having exited or planned to exit more than 100 facilities (about 21 percent of worldwide property), with approximately 72 percent of that space vacated as of July 31, 2003; lease payments expected through at least the next 5 years.
2003-07-31restructuringin_progress14,0002001-10-01GlobalAll segmentsMD&A
f5-10q / Qwen3.6-27B-Q8_0
Cumulative reduction of approximately 14,000 people across 2001, 2002, and 2003 plans as of end of Q3 2003. Includes ~12,500 involuntary terminations and ~1,500 net attrition.
2003-07-31restructuringin_progress8,4002001-10-01GlobalTest and Measurement, Semiconductor ProductsUSD 527 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2001 Plan: Reduced workforce by approx. 8,400 jobs. Total cost through July 31, 2003 was $527 million.
2003-07-31restructuringin_progress2,2002002-08-19GlobalTest and Measurement, IT SupportUSD 160 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2002 Plan: Reduced workforce by approx. 2,200 as of July 31, 2003. Total cost through July 31, 2003 was $160 million.
2003-07-31restructuringin_progress3,4002003-02-21Primarily U.S.Test and Measurement, Semiconductor Products, R&DUSD 255 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2003 Plan: Reduced workforce by approx. 3,400 as of July 31, 2003. Total cost through July 31, 2003 was $255 million.
2003-07-31plant_closurecompleted3002003-07-31United KingdomSemiconductor ProductsMD&A
f5-10q / Qwen3.6-27B-Q8_0
Closure of fabrication facility in U.K., eliminating approx. 300 jobs. Production transferred to Singapore.
2003-04-30restructuringin_progress8,1002001-10-312003-07-31Global (U.S., Korea, Japan and other countries)Primarily Test and Measurement and Semiconductor Products; support functions across all segmentsUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Cumulative program headcount reduction since fiscal 2001, not a current-quarter figure; $8M charge in fiscal 2003 to date ($519M cumulative). Includes exit of 100+ facilities (~4.0M sq ft, ~21% of worldwide property; ~70% vacated at 4/30/03). ~$13M severance for ~300 employees at one U.S. facility remains unpaid; announcement date approximate (initiated fiscal Q4 2001).
2003-04-30restructuringin_progress2,1002002-08-192003-10-31Global (all regions)Manufacturing and field operations serving wireline markets within Test and Measurement; IT support servicesUSD 43 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Target was 2,500 job cuts to reach ~$1.6B quarterly operating cost structure; 2,100 reduced as of 4/30/03. Charge is fiscal 2003 to date ($160M cumulative). Company anticipates a further ~700-person reduction by end of fiscal Q4 2003.
2003-04-30restructuringin_progress1,5002003-02-212003-10-31Primarily United States; globalAll businesses, with significant reductions in Test and Measurement and Semiconductor Products, including R&D and support functionsUSD 122 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced ~4,000 job cuts to cut quarterly operational costs by $125M; 1,500 reduced as of 4/30/03. Charge covers plan inception (Jan 31, 2003) through 4/30/03. Across all plans, company anticipates an additional ~3,500-person reduction through the first half of fiscal 2004 (overlaps remaining 2002/2003 plan targets — do not sum).
2003-04-30plant_closurecompleted2003-04-302003-04-30Newark, California, United StatesSemiconductor ProductsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Production ceased and facility closed at the end of the second quarter; expected operating cost reduction of ~$6M per quarter from fiscal 2003 second half onward. Employees affected not disclosed.
2003-04-30restructuringin_progress2001-10-01GlobalTest and Measurement, Semiconductor Products, Support ServicesUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Initiated Q4 2001. Total cost through Apr 30, 2003 was $519M. Q2 2003 charge of $8M related to facility consolidation and asset impairments. Workforce reduction of ~8,100 jobs substantially complete.
2003-04-30restructuringin_progress2002-08-192003-10-31GlobalTest and Measurement, IT Support ServicesUSD 43 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Initiated Q4 2002. Targeted 2,500 job cuts; ~2,100 reduced as of Apr 30, 2003. Anticipate another 700-person reduction by end of Q4 2003. YTD 2003 charge of $43M.
2003-04-30restructuringin_progress1,5002003-02-21Global (primarily U.S.)Test and Measurement, Semiconductor Products, R&D, Support ServicesUSD 122 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Initiated Q1 2003. Announced 4,000 job cuts; ~1,500 reduced as of Apr 30, 2003. YTD 2003 charge of $122M. Includes facility consolidation and asset impairments.
2003-01-31restructuringin_progress8,0002001-01-012003-07-31Global (U.S., Korea, Japan facility exits)Primarily test and measurement and semiconductor products; support services across all segmentsUSD 511 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Cumulative cost through 2003-01-31 ($154M in 2001, $357M in 2002); no charge in Q1 2003. Workforce reduction of ~8,000 completed by end of Q4 2002; ~$17M severance for ~400 employees at two U.S. facilities remains unpaid, expected complete by Q3 FY2003. Facility exits cover >3.6M sq ft (~19% of worldwide property), ~60% vacated as of quarter end.
2003-01-31restructuringin_progress2,5002002-08-192003-07-31Global (all regions)Manufacturing and field operations serving wireline markets within test and measurement; information technology support servicesUSD 42 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Q1 FY2003 charge of $42M ($37M workforce reduction, $5M asset impairment); cumulative cost $159M ($117M in 2002, $42M in 2003). Approximately 1,000 of the 2,500 positions reduced as of 2003-01-31; remaining savings expected by mid-2003. Target: $50M quarterly operational cost reduction at $1.6B revenue.
2003-01-31restructuringannounced4,0002003-02-212003-10-31GlobalAll segments; test and measurement expected to account for approximately half of savings; semiconductor products slightly less than 20%subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced 2003-02-21, after quarter close; no charges taken in Q1 2003. Targets breakeven cost structure at $1.45B quarterly revenue and $125M quarterly cost reduction by end of Q4 FY2003.
2003-01-31restructuringin_progress2001-10-01GlobalTest and Measurement, Semiconductor Products, Support ServicesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2001 Plan. No charges incurred in Q1 2003. Total cost through Jan 31, 2003 is $511 million. Workforce reduced by approx 8,000 jobs previously.
2003-01-31restructuringin_progress1,0002002-08-192003-06-30GlobalTest and Measurement, IT Support ServicesUSD 42 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
2002 Plan. Reduced workforce by approx 1,000 as of Jan 31, 2003. Total charge in Q1 2003 was $42 million (includes $5M asset impairment). Plan to reduce workforce by 2,500 total.
2003-01-31restructuringannounced4,0002003-02-212003-10-31GlobalGlobalsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0
2003 Plan. Announced Feb 21, 2003. Intention to reduce workforce by 4,000 jobs in addition to previously-announced cuts. No charges taken in Q1 2003.
2002-10-31restructuringcompleted7,7002001-08-20All regions; all expense categories and most segmentsPrimarily test and measurement and semiconductor products, plus support services (sales and marketing, finance, administration) across all segmentsUSD 175 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Substantially complete as of October 31, 2002. Reduction of ~7,700 comprises ~6,400 involuntary terminations and ~1,300 net attrition; announced target was 8,000 jobs (initial announcement of ~4,000 jobs, about 9% of workforce, on August 20, 2001, expanded November 15, 2001 by an additional ~4,000). $175M is the FY2002 workforce-reduction charge; ~$210M cash severance paid in FY2002; cumulative plan charges of $511M ($154M FY2001 plus $357M FY2002); savings of approximately $880M realized in FY2002.
2002-10-31plant_closurein_progress2001-08-20All regions, particularly the U.S. and JapanAll three segments; mostly sales and administrative office space, plus a small number of production facilities consolidated into fewer sitesUSD 182 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Component of the 2001 Plan; workforce reductions tracked in the parent restructuring record. Exit (completed or planned) of more than 100 production, support and sales facilities or parts of facilities, over 3.6 million square feet (~19% of worldwide property); ~40% vacated as of October 31, 2002. FY2002 charges of $182M comprise $53M facility-consolidation costs (lease terminations and anticipated sublease losses) plus $129M property, plant and equipment impairment, of which one production facility in Kobe, Japan accounted for ~$60M (~80% of that facility's net book value). Lease payments on vacated properties continue for at least the next five years.
2002-10-31restructuringin_progress2,5002002-08-192004-01-31Primarily test and measurement (manufacturing and field operations serving wireline markets); related equipment impairment primarily in semiconductor products group, SingaporeUSD 117 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Targets reduction of ~2,500 jobs to cut operational costs by $50M per quarter and reach profitability at quarterly revenue of ~$1.6B; only ~300 reductions completed as of October 31, 2002 (implementation began late in Q4 FY2002), with the majority of quarterly savings expected by mid-2003. FY2002 charge of $117M comprises $83M workforce-reduction (severance) charges and $34M asset impairment on machinery and equipment (equipment to be sold, research consolidated to the U.S.). Completion expected no later than fiscal first quarter 2004 (quarter ending January 31, 2004).
2002-10-31restructuringcompleted7,7002001-08-202002-10-31WorldwideTest and measurement; Semiconductor products; corporate and shared support servicesUSD 357 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Two-step program: about 4,000 announced 2001-08-20 and a further 4,000 on 2001-11-15. Actual reduction of approximately 7,700 (about 6,400 involuntary, 1,300 net attrition) cumulative through 2002-10-31. Charge shown is FY2002 only; cumulative program cost was $511M ($154M in FY2001). Substantially complete at fiscal year-end, with lease payments on vacated properties continuing at least five more years.
2002-10-31restructuringin_progress2,5002002-08-192004-03-31WorldwidePrimarily test and measurement — wireline manufacturing and field operationsUSD 117 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Target of $50M in quarterly operational cost reduction to reach profitability at $1.6B quarterly revenue. Approximately 300 employees reduced as of 2002-10-31; majority of the $50M quarterly saving expected by mid-2003. Charge shown is FY2002 activity only.
2002-10-31plant_closurein_progress2001-08-20Worldwide, concentrated in the United States and JapanAll three segments — production, support and sales facilitiesrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Component of the 2001 Plan, not a separate program. More than 100 facilities or facility portions exited or planned for exit, over 3.6 million square feet (about 19% of worldwide property); approximately 40% vacated as of 2002-10-31. No separate employee count or charge disclosed — charges are included in the 2001 Plan record above.
2002-10-31restructuringcompleted7,7002001-08-202002-10-31GlobalTest and Measurement, Semiconductor Products, Support ServicesUSD 511 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
2001 Plan: Reduced workforce by approx. 7,700 (6,400 involuntary, 1,300 attrition). Substantially complete as of Oct 31, 2002. Total expenses incurred through Oct 31, 2002 were $511 million.
2002-10-31restructuringin_progress3002002-08-192004-03-31GlobalTest and Measurement (Wireline)USD 117 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
2002 Plan: Reduced workforce by approx. 300 as of Oct 31, 2002. Total expected reduction is 2,500. Plan expected to complete no later than Q1 2004. Charges through Oct 31, 2002 were $117 million.
2002-10-31restructuringin_progress7,7002001-08-202002-10-31GlobalTest and Measurement; Semiconductor Products; Support ServicesUSD 511 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
The '2001 Plan' involved a workforce reduction of approximately 8,000 people. As of October 31, 2002, the company reduced its workforce by approximately 7,700 (6,400 involuntary terminations and 1,300 net attrition). The plan was substantially complete as of October 31, 2002. Total expenses incurred through Oct 31, 2002 were $511 million ($154 million in 2001 and $357 million in 2002).
2002-10-31restructuringin_progress3002002-08-192004-03-31GlobalTest and Measurement (Wireline)USD 117 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
The '2002 Plan' announced on August 19, 2002, intended to reduce operational costs by $50 million per quarter. As of October 31, 2002, the workforce was reduced by approximately 300. The company expects to reduce the workforce by 2,500 in total by completion. Expected completion is no later than the first quarter of 2004. Total charge recorded in 2002 was $117 million.
2002-07-31restructuringin_progress4,0002001-08-202002-12-31GlobalAll regions and most segmentsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Original plan to eliminate approximately 4,000 jobs. Program-wide, approximately 7,100 positions had been eliminated as of July 31, 2002 against a total plan of 8,000, with completion expected by end of calendar 2002. Charges are disclosed at program level ($78M in Q3; $218M YTD), not by announcement. $42M of workforce-related payments accrued at July 31, 2002 to be paid to about 800 employees in Q4 2002.
2002-07-31restructuringin_progress4,0002001-11-152002-12-31GlobalAll regions and most segmentsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Enhancement of the August 2001 plan adding approximately 4,000 further job eliminations; components are workforce reduction, excess-facility consolidation, and asset impairment.
2002-07-31restructuringannounced2002-08-19GlobalOperations most impacted by weak telecommunications marketssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Post-quarter announcement of intent to cut operational costs by $50 million per quarter, entailing job cuts beyond the 8,000 previously announced; additional restructuring charges expected in Q4 2002 and first half of fiscal 2003, not yet estimable. Disclosed in MD&A restructuring discussion.
2002-07-31restructuringin_progress7,1002001-08-202002-12-31GlobalAll segmentsUSD 218 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Plan announced Aug 20, 2001 and expanded Nov 15, 2001 to reduce workforce by 8,000. As of July 31, 2002, reduced by approx 7,100. Total charges for nine months ended July 31, 2002 were $218 million.
2002-07-31restructuringannounced2002-08-19GlobalAll segmentsMD&A
f5-10q / Qwen3.6-27B-Q8_0
Announced intention to further reduce operational costs by $50 million per quarter. Additional job cuts expected beyond previous 8,000. Charges expected in Q4 2002 and first half of 2003.
2002-04-30restructuringin_progress4,0002001-08-202002-07-31GlobalCompany-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
First of two 2001 workforce-reduction announcements totaling approximately 8,000 jobs; approximately 6,000 positions had been eliminated cumulatively as of April 30, 2002. Footnote expects substantial completion by end of fiscal Q3 2002, while MD&A states completion by the fourth quarter of 2002. Charges are disclosed only in aggregate across both announcements (approximately $35M in Q2 and $140M in the six months, including asset impairment), so no charge is attributed to this record.
2002-04-30restructuringin_progress4,0002001-11-152002-07-31GlobalCompany-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Second of two 2001 announcements, described as additional to the August 2001 plan. Workforce-reduction charges in the six months ended April 30, 2002 were $93M in Q1 and $32M in Q2, with a remaining severance liability of $33M at April 30, 2002; these are program-level amounts not split between the two announcements.
2002-04-30otherin_progress12002-02-262002-05-31United StatesExecutive (Chief Operating Officer)USD 2 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Executive Vice President and COO resignation effective March 1, 2002 with employment ending on or before May 31, 2002; includes a $2 million gross severance bonus and full acceleration of unvested stock options.
2002-04-30restructuringin_progress6,0002001-08-202002-07-31GlobalAll segmentsUSD 140 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Consolidated count of workforce reduction from plans announced Aug 2001 and Nov 2001. Charges include severance and asset impairment.
2002-01-31restructuringin_progress4,0002001-08-202002-07-31GlobalAll segmentsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
First of two announced plans to eliminate approximately 4,000 jobs each. Approximately $105 million of restructuring and asset impairment charges were recognized in the quarter across both plans; the filing does not allocate the charge between the two announcements. Cumulative workforce reduction of approximately 5,000 at 2002-01-31 spans both plans.
2002-01-31restructuringin_progress4,0002001-11-152002-07-31GlobalAll segmentsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Second announced plan, described as in addition to the August 20, 2001 plan. Company expects to substantially complete both plans by the end of fiscal Q3 2002. Quarterly restructuring charges of $105 million comprise $48M in cost of products and services, $12M in R&D, and $45M in SG&A, including $12M of asset impairment.
2002-01-31restructuringin_progress4,0002001-08-202002-09-30GlobalAll segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Plan announced Aug 20, 2001 to eliminate approx. 4,000 jobs. Part of broader effort.
2002-01-31restructuringin_progress4,0002001-11-152002-09-30GlobalAll segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Plan announced Nov 15, 2001 to eliminate approx. 4,000 jobs. Combined with prior plan, workforce reduced by approx. 5,000 as of Jan 31, 2002.
2001-10-31restructuringin_progress4,0009%2001-08-202002-06-30USD 175 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
Plan to cut discretionary costs, reduce the workforce about nine percent and reduce the number of occupied sites. Total plan cost estimated at $175 million; $154 million recognized in FY2001 ($79M in cost of products/services, $17M in R&D, $58M in SG&A). Approximately 3,000 employees separated in H2 FY2001; $65 million of severance paid by 2001-10-31 with the remaining liability expected to be utilized during 2002. Completion timing disclosed as 'by the middle of' fiscal 2002.
2001-10-31restructuringannounced4,00010%2001-11-152002-06-30subsequent_events
f5-10k / GLM-5.3-flash-HTML
Additional 4,000 job eliminations (approximately 10 percent of the workforce) announced after fiscal year-end, targeted for completion by the middle of 2002. MD&A states the combined estimated cost of the August and November reduction plans is $350 million. The announcement also included reinstating the 10% pay reduction for approximately 2,000 senior managers starting Q1 FY2002 and an effective 5% salary reduction for other employees from February 2002.
2001-10-31divestiture_reductioncompleted2000-11-172001-08-01Healthcare Solutions (discontinued operations)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML
Healthcare solutions business sold to Koninklijke Philips Electronics N.V. under an Asset Purchase Agreement dated November 17, 2000; sale completed August 1, 2001 for a total purchase price of $1.7 billion (after-tax gain of $646 million). No employee headcount transferred or affected was disclosed in the filing.
2001-10-31othercompleted2001-10-31Global (where legally permissible)MD&A
f5-10k / GLM-5.3-flash-HTML
10% reduction in pay instituted from May 1 through October 31, 2001, applicable to all employees globally wherever legally permissible; implemented via a 10% reduction in hours for certain employees in accordance with local law. Subsequently reinstated for ~2,000 senior managers from Q1 FY2002 and extended at 5% for other employees effective February 2002 (see the November 15, 2001 announcement).
2001-10-31acquisition_additioncompleted2001-01-052001-01-05Test and Measurementbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML
Acquired Objective Systems Integrators, Inc. for approximately $716 million ($690 million cash plus fair value of options granted); OSI became part of the test and measurement business. Headcount acquired was not disclosed.
2001-10-31acquisition_additioncompleted2001-07-202001-07-20Belgiumother
f5-10k / GLM-5.3-flash-HTML
All shares of Sirius Communications N.V. acquired in exchange for 1,461,196 Agilent common shares issued in reliance on Regulation S. Headcount acquired was not disclosed.
2001-10-31restructuringin_progress4,0009%2001-08-202002-06-30WorldwideCompany-wideUSD 175 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Plan to cut about nine percent of workforce by mid-2002; $154M of the $175M total cost recognized in FY2001 ($79M cost of products and services, $17M R&D, $58M SG&A). Approximately 3,000 employees actually separated in the second half of FY2001; $65M severance paid by year-end, remainder payable during 2002.
2001-10-31restructuringannounced4,00010%2001-11-152002-06-30WorldwideCompany-widesubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Announced after fiscal year-end but before filing. MD&A states combined cost of both announced plans estimated at $350M, of which $154M recognized in FY2001. Paired with reinstatement of a 10 percent pay reduction for about 2,000 senior managers and a 5 percent salary reduction for other employees effective February 2002.
2001-10-31divestiture_reductioncompleted2000-11-172001-08-01WorldwideHealthcare solutionsdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Sale of healthcare solutions business to Koninklijke Philips Electronics for $1.7B completed 2001-08-01; headcount transferred not disclosed. Agilent restricted from competing in certain medical products for five years.
2001-10-31acquisition_additioncompleted2001-01-05United StatesTest and measurementUSD 716 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Objective Systems Integrators, Inc. for approximately $716M ($690M cash); acquired headcount not disclosed.
2001-10-31acquisition_additioncompleted2001-01-31JapanCompany-wideUSD 99 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Completed purchase of Yokogawa's remaining 4.2 percent interest in Agilent Technologies Japan, Ltd. for approximately $99M, final step of a $521M three-step transaction; headcount impact not disclosed.
2001-10-31restructuringin_progress4,0009%2001-08-202002-06-30GlobalAll segmentsUSD 154 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Plan announced August 20, 2001 to reduce workforce by approx 4,000 (9%) by mid-2002. $154 million recognized in 2001. Total estimated cost of plans is $350 million.
2001-10-31restructuringannounced4,0002001-11-15GlobalAll segmentssubsequent_events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
Announced November 15, 2001 intention to further reduce workforce by approx 4,000 people. Part of total $350 million restructuring cost estimate.
2001-10-31restructuringin_progress4,0009%2001-08-202002-06-30WorldwideAll segmentsUSD 175 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
Plan to reduce workforce by approximately 4,000, or about nine percent, by the middle of 2002. Total cost estimated at $175 million, of which $154 million recognized in 2001.
2001-10-31restructuringannounced4,0002001-11-15WorldwideAll segmentssubsequent_events
f5-10k / Qwen3.6-27B-Q8_0
Announced intention to further reduce workforce by approximately 4,000 people. Combined with prior plan, total estimated cost is $350 million.
2001-10-31acquisition_additioncompleted2001-01-052001-01-05WorldwideTest and MeasurementUSD 716 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
Acquired Objective Systems Integrators, Inc. for approximately $716 million. Headcount not explicitly disclosed.
2001-10-31restructuringin_progress4,0009%2001-08-202002-06-30USD 154 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Plan announced 2001-08-20 to cut about 4,000 jobs, roughly nine percent of workforce, by mid-2002; total estimated plan cost $175 million, of which $154 million was recognized in FY2001 ($79M in cost of products and services, $17M in R&D, $58M in SG&A); $65 million of severance paid by 2001-10-31 with the remainder expected to be paid during 2002. Filer also states approximately 3,000 employees were reduced in the second half of 2001 under its announced workforce measures — treated as execution of this program, not a separate action. Expected completion date approximated from 'by the middle of next year'.
2001-10-31reduction_in_forceannounced4,00010%2001-11-152002-06-30subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Post-fiscal-year-end announcement of an additional 4,000 job eliminations, about 10 percent of the workforce, targeted for mid-2002; no charge quantified in the filing. Expected completion date approximated from 'by the middle of 2002'.
2001-10-31divestiture_reductioncompleted2000-11-172001-08-01GlobalHealthcare Solutions Groupdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Sale of the healthcare solutions business to Philips completed 2001-08-01 for a total purchase price of $1.7 billion; results presented as discontinued operations for all periods. Headcount transferred with the business is not disclosed in the filing.
2001-10-31restructuringin_progress4,0009%2001-08-202002-06-30GlobalAll segmentsUSD 175 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
Plan to reduce workforce by approximately 4,000, or about nine percent, by the middle of next year. Total cost estimated at $175 million, of which $154 million recognized in fiscal 2001. In the second half of 2001, Agilent reduced its workforce by approximately 3,000 employees.
2001-10-31restructuringannounced4,00010%2001-11-152002-06-30GlobalAll segmentssubsequent_events
f5-10k / Qwen3.6-27B-Q8_0
Announced elimination of an additional 4,000 jobs, approximately 10 percent of workforce, by the middle of 2002.
2001-07-31restructuringannounced4,0009%2001-08-202002-06-30GlobalCompany-widesubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Announced post-quarter; reduction of about nine percent of workforce by mid-2002. No severance charge disclosed in this filing. MD&A also cites hiring freeze, reduced temporary labor, discretionary spending cuts, and a temporary 10% global pay reduction effective 2001-05-01 through 2001-11-01.
2001-07-31divestiture_reductioncompleted2000-11-172001-08-01GlobalHealthcare Solutionsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Sale to Philips completed 2001-08-01 for $1.7 billion; operational facilities and associated assets and liabilities transferred. Headcount transferred not disclosed. Agilent will provide transitional support services to Philips for one year.
2001-07-31restructuringannounced4,0009%2001-08-202002-06-30GlobalAll segmentssubsequent_events
f5-10q / Qwen3.6-27B-Q8_0
Management announced workforce reduction of approximately 4,000 people, or about nine percent, by the middle of next year.
2001-04-30otherannounced2001-04GlobalAll employeesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Temporary 10% pay reduction for all employees globally, effective May 1, 2001, implemented via reduced hours where required by local law.
2001-04-30otherin_progressGlobalAll functionsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Hiring freeze, significant reduction in temporary workers, reduced discretionary spending, and short-term manufacturing closures initiated in response to demand slowdown.
2001-04-30restructuringin_progress2001-10-31Not specifiedHealthcare Solutions (discontinued operations)USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Remaining $9M of $21M restructuring liability from Q4 2000 for healthcare solutions business; expected to be utilized in second half of fiscal 2001. No employee count disclosed.
2001-04-30acquisition_additioncompleted2001-01-052001-01-05Not specifiedTest and Measurementbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Objective Systems Integrators, Inc. for $716M total purchase price; no headcount added disclosed.
2001-04-30divestiture_reductionin_progress2000-11-172001-10-31Not specifiedHealthcare Solutionsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Agreed to sell healthcare solutions business to Philips for approximately $1.7 billion; antitrust clearance received; no headcount removed disclosed.
2001-04-30otherin_progress2001-04-01GlobalAllMD&A
f5-10q / Qwen3.6-27B-Q8_0
Announced temporary 10% reduction in pay effective May 1, 2001, applying to all employees globally wherever possible. Implemented via 10% reduction in hours for certain employees.
2001-04-30otherin_progress2001-04-30GlobalAllMD&A
f5-10q / Qwen3.6-27B-Q8_0
Frozen hiring and cut back significantly on use of temporary workers to address recent slowdown in demand.
2001-01-31restructuringin_progress2001-10-31Healthcare SolutionsUSD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Restructuring of healthcare solutions business originally charged in Q4 FY2000 ($21M total); $14M liability remaining, expected to be utilized in H2 FY2001. No employee count disclosed.
2001-01-31restructuringin_progress2001-06-30Healthcare SolutionsUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Remaining liability from prior quarter restructuring; expected to be utilized in second half of 2001.
2001-01-31acquisition_additioncompleted2001-01-052001-01-05Test and MeasurementUSD 684 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0
Acquisition of Objective Systems Integrators, Inc. (OSI). Headcount not disclosed.
2001-01-31acquisition_additioncompleted2001-01-012001-01-01JapanUSD 98 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0
Acquisition of remaining 4.2% interest in Agilent Technologies Japan, Ltd. from Yokogawa Electric Corporation. Headcount not disclosed.
2000-10-31restructuringin_progress5962000-082001United States, Asia Pacific, EuropeHealthcare solutionsUSD 21 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML
August 2000 restructuring of the healthcare solutions business combining workforce reductions via severance programs with consolidation of business operations. Affected population comprises 396 regular employees who accepted severance packages and 200 temporary employees terminated; the 596 count is the sum of these two disclosed populations. The $21M pre-tax charge comprises $13M estimated severance benefits and $8M non-cash asset writedowns. $2M of severance had been paid as of October 31, 2000, with the remaining liability expected to be utilized during 2001 (basis for expected completion year). Also described in Item 1/MD&A; extracted once from the footnote per deduplication rule.
2000-10-31divestiture_reductionannounced2000-11-172001-06-30GlobalHealthcare solutionssubsequent_events
f5-10k / GLM-5.3-flash-HTML
Agreement to sell the entire healthcare solutions business to Koninklijke Philips Electronics, N.V. for approximately $1.7 billion. Virtually all business employees, including 100% of business-dedicated infrastructure employees, will be offered employment by or transferred to Philips; estimated net assets to transfer are $400 million. Agilent restricted from competing in development, manufacturing, selling or servicing of certain medical products for five years. Sale price is consideration, not a charge. Segment headcount was approximately 5,000 at October 31, 2000, but the filer does not state a specific affected-employee figure for this transaction. Expected completion by mid-calendar year 2001, subject to regulatory approvals and closing conditions.
2000-10-31restructuringin_progress5962000-082001United States, Asia Pacific and EuropeHealthcare solutionsUSD 21 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Comprises 396 regular employees accepting severance packages plus 200 temporary employees terminated; charge of $21M pre-tax ($13M severance, $8M non-cash asset writedowns); $2M severance paid at year-end, remainder expected to be utilized during 2001
2000-10-31divestiture_reductionannounced2000-11-172001-06-30GlobalHealthcare solutionssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Sale of healthcare solutions business to Philips for approximately $1.7 billion; virtually all business employees, including dedicated infrastructure staff, to be offered employment by or transferred to Philips; no headcount quantified; net assets to transfer estimated at $400 million
2000-10-31acquisition_additionannounced2001-01-052001-01-05Not disclosedTest and measurementUSD 684 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Acquisition of Objective Systems Integrators, Inc. completed for approximately $684 million in cash; acquired headcount not disclosed
2000-10-31restructuringin_progress5962000-082001-10-31United States, Asia Pacific, EuropeHealthcare SolutionsUSD 21 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML
396 regular employees accepted severance packages and 200 temporary employees terminated. $21 million pre-tax charge ($13 million severance, $8 million asset writedowns). $2 million paid as of Oct 31, 2000; remainder expected utilized in 2001.
2000-10-31restructuringin_progress5962000-082001-12-31United States, Asia Pacific, EuropeHealthcare SolutionsUSD 21 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0
396 regular employees accepted severance; 200 temporary employees terminated. $13M severance, $8M asset writedowns. Liability expected utilized during 2001.
2000-07-31restructuringannounced6502000-07-312000-10-31United States, Asia Pacific, EuropeHealthcare SolutionsUSD 25 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML
Subsequent-event announcement; exact announcement date not specified beyond 'subsequent to July 31, 2000'. Approximately 450 regular and 200 temporary employees. Expected annual savings of ~$80M starting 2001. Charge expected in fiscal Q4 2000 (quarter ending Oct 31, 2000).
2000-07-31restructuringannounced6502000-07-31United States, Asia Pacific, EuropeHealthcare SolutionsUSD 25 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0
Announced subsequent to July 31, 2000. Includes approx. 450 regular and 200 temporary employees. One-time charge of approx. $25 million expected in Q4 2000.
2000-01-31voluntary_separationcompleted1,6501998-10-312000-01-31GlobalManufacturing and other positions included in cost of products and servicesUSD 78 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0
Approximately 1,650 employees accepted voluntary severance incentive packages by the October 31, 1998 deadline. Approximately 80% were in manufacturing or other positions included in cost of products and services. The entire $78 million severance charge has been paid as of January 31, 2000.
1999-10-31voluntary_separationcompleted1,6501998-01-011998-10-31GlobalAll four business segments; primarily manufacturingUSD 78 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY1998 program; approximately 1,650 employees accepted voluntary severance packages by the October 31, 1998 deadline. Approximately 80% were in manufacturing or cost-of-products positions. Severance portion of the $163M total pre-tax restructuring charge. $69M paid as of October 31, 1999.
1999-10-31restructuringcompleted1998-10-011999-10-31GlobalSemiconductor productsUSD 51 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML
FY1999 charge for write-down of a building under construction for eight-inch semiconductor wafer manufacturing. Construction stopped after October 1998 decision to outsource wafer production. No associated headcount reduction disclosed for this charge.
1999-10-31divestiture_reductioncompleted1999-01-011999-10-31GlobalMultiple — portions of businesses sold to third partiesother
f5-10k / MiMo-V2.6-Flash-fp8-HTML
Gross proceeds from divestitures were $121 million in FY1999; gains of $54 million recognized in other income. No headcount associated with divestitures disclosed.
1999-10-31voluntary_separationcompleted1,6501998-10-311998-10-31WorldwideAll segmentsUSD 78 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0
Approximately 1,650 employees accepted voluntary severance incentive packages by the October 31, 1998 deadline. $78 million in severance charges recorded in FY1998. Approximately 80% were in manufacturing or other positions included in cost of products and services.